

# **ACPE Accredited Provider**

# #0122

# **Annual Pharmacy CE Summary Report**


# **CE Activities of 2021**

Acurity<sup>®</sup> is a wholly owned company of Premier, Inc.

# **Report Contents**

Live CE Activity Completion 2012 -2021
Summary of CE Hours Provided in 2021 4
2021 Evaluation Scoring Reports
CE Teleconference Evaluations Report – Pharmacists5
CE Teleconference Evaluations Report – Pharmacy Technicians
Pharmacy Practice Forum Evaluations Report7
Antimicrobial Stewardship Forum Evaluations Report
Other Live CE Evaluations Report9
Breakthroughs CE Evaluations Report10
Homestudy CE Evaluations Report – Pharmacists
Homestudy CE Evaluations Report – Pharmacy Technicians
2021 CE Comments Reports
CE Teleconference Comments Report15
Pharmacy Practice Forum Comments Report16
Antimicrobial Stewardship Forum Comments Report
Homestudy CE Comments Report18
Other Live CE Comments Report 20
Breakthroughs Comments Report 21
2021 Overall CE Activity Ratings

# **CE Program Participation**



Averages for 2021 CE activities (numbers are averages per CE activity based on annual registration and CE completion):

- Monthly CE Webinars: 545 registrants; 409 completed CE requirements
- Pharmacy Practice Forum: 505 registrants; 363 completed CE requirements
- Antimicrobial Stewardship Forum: 545 registrants; 382 completed CE requirements

499 registrants; 265 completed CE requirements for Premier Member Meeting CE in Dec 2021

Homestudy CE: 42 (including Breakthroughs) activities offered; average of 57 registrants each; average of 31 CE recipients each

# Annual CE Activity Report – 2021

Total Number of Live CE Activities Offered
31
Total Hours of Live CE Offered
31
Total Number of Homestudy CE Activities Offered
42
Hours of Homestudy CE Offered
43.25
Hours of Pharmacist CE Offered (Live + Homestudy)
74.25
Hours of Pharmacy Technician CE Offered
73.25
Active Learning Strategies Use in CE Activities
Q&A with speaker; polling questions; case discussions

# Premier/Acurity, Inc. CE Teleconference Evaluations Report - Pharmacists 2021

Date and Working Program Title	Soeaker Name, e-mail address	Credit Hrs	Total # of Registrants	Total # of CE Recipients	# of Pharmacist s Receiving CE	Activity met educational needs	Quality of faculty was satisfactory	Educational materials were useful	Actively participated in activity	Teaching methods were effective	Learning assessment activities were appropriate	Objectives were met	Overall Activity Ratino	Specialty Areas	Focus Areas (Outcomes, Safety, Best Practices)
January 27, 2021: COVID-19 Vaccine: Science and Health-system Logistics	Karen McConnell, PharmD, FCCP, FASHP, BCPS; mailto:karenmcconnell@catholichealth.net Eric Yager, PhD; Eric.Yager@acphs.edu	1.0	587	426	380	4.56	4.56	4.56	4.46	4.55	4.55	4.56	4.54	COVID-19, Immunizations	Safety, Best Practices
February 25, 2021: Integrating Biosimilars Into Health Systems	Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA; Soefje.Scott@mayo.edu	1.0	527	387	357	4.39	4.43	4.38	4.35	4.39	4.39	4.41	4.39	Biosimilars, Cost-savings	Best Practices
	John A. Armitstead, MS, RPh, FASHP; john.armitstead@leehealth.org	1.0	493	390	348	4.35	4.38	4.36	4.34	4.37	4.38	4.39	4.37	Dharmaoy	Best Practices
	Bryan Blackwelder, PharmD; Bryan.Blackwelder@bmcjax.com	1.0	571	454	403	4.47	4.46	4.46	4.43	4.45	4.46	4.48	4.46	Med Safety	Safety, Best Practices, Outcomes
May 18 2021: Managing the ICLI Patient with Obesity	Brian Erstad, PharmD; erstad@pharmacy.arizona.edu	1.0	537	417	369	4.45	4,47	4.44	4.43	4.41	4.44	4.48	4.44		Best Practices, Outcomes
June 22, 2021: A Daily Infusion of Outpatient Parenteral Antibiotic Therapy (OPAT) Education	Monica V. Mahoney, PharmD, BCPS AQ-ID, BCIDP; mmahoney@bidmc.harvard.edu	1.0	514	392	347	4.44	4.49	4.44	4.39	4.45	4.45	4.46	4.45	Antimicrobial Stewardship,	Best Practices, Outcomes
July 28, 2021: Opioid Stewardship	Nicholas Quinn, PharmD, BCCCP; nquinn@montefiore.org Jennifer Halsey, MS, PharmD, BCPS; jhalsey@peacehealth.org	1.0	562	422	377	4.43	4.45	4.43	4.4	4.41	4.42	4.45	4.43	Onioide	Safety, Best Practices, Outcomes
	Heather Torbic, PharmD, BCCCP, BCPS; torbich@ccf.org	1.0	515	346	305	4.44	4.49	4.45	4.41	4.44	4.45	4.46	4.45	Pulmonary Diseases, New Drugs, Cost- Savings	Best Practices, Outcomes
September 23, 2021: Update on COVID-19 Therapeutics: What Have We Learned So Far? (Working Title)	Debra Goff, PharmD, FIDSA, FCCP; debbie.goff@osumc.edu	1.0	565	428	374	4.51	4.52	4.49	4.45	4.49	4.5	4.51	4.50	,	Best Practices, Outcomes
October 19, 2021: An Inflection Point for Healthcare: Washington DC Advocacy Update	Soumi Saha, PharmD, JD; soumi_saha@premierinc.com	1.0	524	415	359	4.49	4.52	4.46	4.44	4.47	4.48	4.51	4.48	Pharmacy Law	Best Practices
	Ashley Siryk, PharmD; asiryk@mhs.net	1.0	546	388	339	4.44	4.46	4.44	4.42	4.43	4.46	4.45	4.44	New Drugs	Best Practices
Management	Judy Cheng, PharmD, MPH, FCCP, BCPS, RPh; judy.cheng@mcphs.edu	1.0	606	439	390	4.53	4.54	4.51	4.49	4.51	4.51	4.53	4.52	CV Diseases	Outcomes
Totals		12.0	6547	4904											

## Premier/Acurity, Inc. CE Teleconference Evaluations Report - Pharmacy Technicians 2021

					# of						Learning				
					Pharmacy	Activity met	Quality of	Educational	Actively	Teaching	assessment				Focus Areas
		Credit	Total # of	Total # of CE	Technicians	educational	faculty was	materials were	participated in	methods were	activities were	Objectives	Overall Activity	Specialty	(Outcomes, Safety, Best
Date and Working Program Title	Speaker Name, e-mail address	Hrs	Registrants	Recipients	Receiving CE	needs	satisfactory	useful	activity	effective	appropriate	were met	Rating	Areas	Practices)
	Karen McConnell, PharmD, FCCP, FASHP, BCPS;													COVID-19,	
January 27, 2021: COVID-19 Vaccine: Science and Health-system Logistics m		1.0	587	426	46	4.43	4.45	4.43	4.21	4.45	4.45	4.4	4.40	Immunizations	Safety, Best Practices
E	ric Yager, PhD; Eric.Yager@acphs.edu													IIIIIIuiiizations	
	Cott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA;	1.0	527	387	30	43	4.33	4.33	4.23	43	43	4.33	4.30	Biosimilars,	Best Practices
¥ ¥ ¥	Soefje.Scott@mayo.edu	1.0	521	307		4.5	4.55	4.55	4.23	4.5	4.5	4.55	4.50	Cost-savings	Dest Flactices
<u></u>	ohn A. Armitstead, MS, RPh, FASHP;	1.0	493	390	42	4.28	4.4	4.3	4.23	4.35	4.33	4.35	4.32	Pharmacy	Best Practices
	ohn.armitstead@leehealth.org	1.0	400	000	72	4.20		4.0	4.20	4.00	4.00	4.00	4.02	Administration	
v	Bryan Blackwelder, PharmD;	1.0	571	454	51	4.23	4.29	4.31	4.21	4.31	4.29	4.31	4.28	Pediatrics,	Safety, Best Practices,
Non-Standard Patient B	Bryan.Blackwelder@bmcjax.com	1.0	5/1	404	51	4.25	4.23	4.51	4.21	4.01	4.25	4.01	4.20	Med Safety	Outcomes
May 18, 2021: Managing the ICU Patient with Obesity	Brian Erstad, PharmD; erstad@pharmacy.arizona.edu	1.0	537	417	48	4.36	4.32	4.38	4.23	4.38	4.38	4.36	4.34	Critical Care,	Best Practices,
						1.00	1.02	1.00	1.20	1.00	1.00	1.00		Drug Dosing	Outcomes
														Antimicrobial	
	lonica V. Mahoney, PharmD, BCPS AQ-ID, BCIDP;	1.0	514	392	45	4.35	4.35	4.35	4.27	4.35	4 33	4.35	4.34	Stewardship,	Best Practices,
(OPAT) Education	nmahoney@bidmc.harvard.edu		014	002	10	1.00	1.00	1.00	1.21	1.00	1.00	1.00		Outpatient	Outcomes
														Services	
	licholas Quinn, PharmD, BCCCP;														
	quinn@montefiore.org	1.0	562	422	45	4.29	4.39	4.29	4.22	4.33	4.31	4.36	4.31	Opioids	Safety, Best Practices,
J	ennifer Halsey, MS, PharmD, BCPS;	-						-							Outcomes
jł	nalsey@peacehealth.org														
														Pulmonary	
· · · · · · · · · · · · · · · · · · ·	leather Torbic, PharmD, BCCCP, BCPS;	1.0	515	346	41	4.24	4.27	4.27	4.24	4.27	4.24	4.29	4.26		Best Practices,
Pulmonary Arterial Hypertension to	orbich@ccf.org													Drugs, Cost-	Outcomes
														Savings	
	Debra Goff, PharmD, FIDSA, FCCP;	1.0	565	428	54	4.44	4.44	4.4	4.35	4.42	4.42	4.45	4.42	COVID-19,	Best Practices,
	ebbie.goff@osumc.edu													Immunizations	Outcomes
<u> </u>	Soumi Saha, PharmD, JD;	1.0	524	415	56	4.34	4.33	4.38	4.31	4.34	4.4	4.34	4.35	Pharmacy Law	Best Practices
	oumi_saha@premierinc.com	-		-											
	shley Siryk, PharmD; asiryk@mhs.net	1.0	546	388	49	4.24	4.33	4.35	4.18	4.29	4.31	4.29	4.28	New Drugs	Best Practices
	udy Cheng, PharmD, MPH, FCCP, BCPS, RPh;	1.0	606	439	49	4.32	4.3	4.3	4.25	4.3	4.3	4.38	4.3	CV Diseases	Outcomes
	udy.cheng@mcphs.edu	-													
Totals		12.0	6547	4904											

## Premier/Acurity, Inc. Pharmacy Practice Forum Evaluations Report 2021

Date and Working Program Title	Speaker Name, e-mail address	Credit Hrs	Total # of Registrants	Total # of CE Recipients	# of Pharmacists Receiving CE	Activity met educational needs	Quality of faculty was satisfactory	Educational materials were useful	Actively participated in activity	Teaching methods were effective	Learning assessment activities were appropriate	Objectives were met	Overall Activity Rating	Specialty Areas	Focus Areas (Outcomes, Safety, Best Practices)
January 14, 2021: Managing Patients with COVID-19: Focus on ICU and ID Patients	Corey Frederick, PharmD, BCPS, BCIDP; cfrederick@mhs.net	1.0	516	375	340	4.41	4.39 4.37	4.38	4.4	4.58	4.4	4.4	4.37	COVID-19	Best Practices, Outcomes
March 10, 2021: Utilizing Technology in Sterile Compounding Areas	Dianeysis H. Avendano PharmD, CPh, BCPS; davendano@mhs.net	1.0	469	343	301	4.4	4.4	4.41	4.4	4.4	4.4	4.4	4.40	Sterile Compounding	Best Practices, Safety
May 5, 2021: Medication Safety: Handling Hazardous Medication	Lilit Smith, PharmD, MBA, BCSCP; LilitS@baptisthealth.net	1.0	519	383	334	4.39	4.42	4.4	4.36	4.39	4.37	4.43	4.39	Hazardous Meds, Safety	Best Practices, Safety
July 14, 2021: A Diverse Healthcare Workforce for America's Present and Future	Regina McClinton, PhD, CDP; reginamc@med.umich.edu	1.0	463	348	306	4.27	4.36	4.28	4.33	4.28	4.31	4.32	4.31	Diversity, Administration	Best Practices
September 9, 2021: Pharmacy Preceptor Development	Suzanne Turner, PharmD, FASHP; suzanne.turner@leehealth.org Carolyn J. Oxencis, PharmD, BCOP; carolyn.oxencis@froedtert.com	1.0	566	405	363	4.4	4.43 4.43	4.43	4.32	4.4	4.42	4.41	4.40	Pharmacy Preceptor Development	Best Practices
November 4, 2021: Insulin: Pharmacy Advancements in Inpatient Distribution and Patient Management	Andy Grimone, PharmD, BCPS; andrew.grimone@vidanthealth.com Jubie Joseph, PharmD; jubie.joseph@snch.org	1.0	497	323	282	4.37	4.4	4.38	4.34	4.39	4.39	4.4	4.4	Pharmacy Administration	Best Practices, Outcomes
Totals		6.0	3030	2177				•	•						

### Premier/Acurity, Inc. Antimicrobial Stewardship Forum Evaluations Report 2021

		<b>n</b> 111	<b>T</b> . 1 # 7	T . 1 # 105	# of	Activity met	Quality of	Educational	Actively	Teaching	Learning assessment	<b>5</b> 1.0		<b>a</b>	Focus Areas
		Credit 	Total # of	Total # of CE		educational	faculty was		participated in		activities	Objectives	Overall Activity	Specialty	(Outcomes, Safety,
Date and Working Program Title	Speaker Name, e-mail address	Hrs	Registrants	Recipients	Receiving CE	needs	satisfactory	were useful	activity	effective	were	were met	Rating	Areas	Best Practices)
February 10, 2021: What's HOT in Antimicrobial Stewardship: Updates	Yi Guo, PharmD, BCIPD; yiguo@montefiore.org	1.0	502	340	311	4.41	4.46	4 4 2	4.35	1 11	4.42	4.45	4.31	Antimicrobial	Best Practices,
from ID Week 2020	Nita Roy, PharmD; RoyN@southcoast.org	1.0	502	540	511	4.41	4.44	4.42	4.55	4.41	7.72	4.45	4.51	Stewardship	Outcomes
April 7, 2021: Laboratory Implementation of CLSI Updates: Recipe for	Wendy Szymczak, PhD, D(ABMM), MT(ASCP);	1.0	444	309	266	4.28	4.32	4.29	4.21	12	4.31	4.31	4.36	Antimicrobial	Best Practices,
Success	wszymcza@montefiore.org	1.0	444	209	200	4.20	4.52	4.29	4.21	4.5	4.51	4.51	4.30	Stewardship	Outcomes
June 2, 2021: Expanding Antimicrobial Stewardship Efforts in the	Julie E. Williamson, PharmD, BCPS;	1.0	478	355	316	4.4	4.45	4.45	4.35	4.42	4.43	4.45	4.42	Antimicrobial	Best Practices,
Outpatient Setting	Julie.Williamson@atriumhealth.org	1.0	4/0	300	310	4.4	4.40	4.40	4.35	4.42	4.43	4.45	4.42	Stewardship	Outcomes
August 11, 2021: Vancomycin AUC Implementations and Outcomes	Erin K. McCreary, PharmD, BCPS, BCIDP; mccrearye3@upmc.edu Emily L. Heil, PharmD, MS, BCIDP, BCPS, AAVIHP; eheil@rx.umaryland.edu Victor Chen, PharmD, BCPS, BCIDP; vic002@health.ucsd.edu	1.0	757	483	446	4.27	4.32	4.28	4.25	4.29	4.31	4.31	4.30	Antimicrobial Stewardship	Best Practices, Outcomes
October 6. 2021: Antimicrobial Stewardship in the Emergency Department: Beyond the Bugs and Drugs	Cierra N. Treu, PharmD, BCCCP; cnt9004@nyp.org	1.0	565	417	373	4.46	4.46	4.48	4.36	4.37	4.43	4.47	4.38	Antimicrobial Stewardship	Best Practices, Outcomes
December 1, 2021: Short and Sweet: Why is Shorter Duration of Antibiotic Therapy Better?	Yuman (Yumi) Lee, PharmD, BCIDP; leey2@stjohns.edu	1.0	524	390	342	4.31	4.37	4.34	4.23	4.34	4.33	4.35	4.32	Antimicrobial Stewardship	Best Practices, Outcomes
Totals		6.0	3270	2294		-		-			-				

#### Premier/Acurity, Inc. Premier Member Meeting, Capstone & Yankee Alliance CE Evaluation Reports 2021

#### Premier Member Meeting

Date and Working Program Title	Speaker Name, e-mail address	Credit Hrs	Total # of Registrants	Total # of CE Recipients	# of Pharmacists Receiving CE			Quality of faculty was satisfactory		Actively participated in activity	Teaching methods were effective	Learning assessment activities were appropriate	Overall Activity Rating	Specialty Areas	Focus Areas (Outcomes, Safety, Best Practices)
2021 Premier Member Meeting CE: Complex Orders: Compliance with Joint Commission Requirements	Jeannell M. Mansur, RPh, PharmD, FASHP, FSMSO, CJCP; jmansur@jcrinc.com	1.0	499	265	227	4.36	4.31	4.36	4.31	4.37	4.32	4.26	4.32	Joint Commission, Pharmacy Administration	Best Practices

#### Capstone CEs

Date and Working Program Title	Speaker Name, e-mail address	Credit Hrs	Total # of Registrants	Total # of CE Recipients	# of Pharmacists Receiving CE		Quality of faculty was satisfactor y	Educational materials were useful	Actively participated in activity	Teaching methods were effective		Objectives were met	Overall Activity Rating	Specialty Areas	Focus Areas (Outcomes, Safety, Best Practices)
January 28, 2021: Managing Patients with COVID-19: Focus		1.0	19	9	9	4.67	4.78	4.78	4.56	4.67	4.56	4.67	4.67	COVID-19	Best Practices, Outcomes
	Corey Frederick, PharmD, BCPS, BCIDP; cfrederick@mhs.net Karen McConnell, PharmD, FCCP,						4.89								Outcomes
April 29, 2021: Measuring the Immeasurable: Measuring Clinical Pharmacy Productivity	FASHP, BCPS; karenmcconnell@catholichealth.net	1.0	15	7	7	4.57	4.57	4.57	4.71	4.86	4.71	4.57	4.65	Pharmacy Administratior	Best Practices, Outcomes
	Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP; kane-gill@pitt.edu	1.0	16	6	6	4.83	4.83	4.83	4.67	4.83	4.67	4.83	4.78	IT, Renal Diseases	Best Practices, Outcomes
October 28, 2021: Data-Driven Formulary Management: Applying Analytic Tools to Drive Efficient Medication Use	Pavel Goriacko, PharmD, MPH, BCPS; pgoriack@montefiore.org Mark Sinnett, PharmD, FASHP; msinnet@montefiore.org	1.0	18	14	14	4.81	4.92 4.88	4.85	4.88	4.81	4.81	4.85	4.85	IT, Pharmacy Administration	Best Practices
Totals			68	36											

#### Yankee Alliance CEs

Date and Activity Topic	Speaker(s)	Credit Hrs	Total # of Registrants		# of Pharmacy Technicians Receiving CE credit	ACTIVILY MEL	Quality of faculty was satisfactor y	Educational materials were useful	Actively participated in activity			Objectives were met	Overall Activity Rating	Specialty Areas	Focus Areas (Outcomes, Safety, Best Practices)
	Soumi Saha, PharmD, JD; soumi_saha@premierinc.com	1.0	13	8	0	4.75	4.75	4.75	4.75	4.75	4.75	4.75	4.75	Pharmacy Law	Best Practices
October 20, 2021: Tools to Transform Pharmacy: Today and	Karen McConnell, PharmD, FCCP, FASHP, BCPS; mailto:karenmcconnell@catholichealth.n et	1.0	12	10	0	4.73	4.73	4.73	4.64	4.73	4.73	4.73	4.72	Pharmacy Administration	Best Practices
Totals			25	18											

### Premier/Acurity Breakthroughs 2021 CEs Evaluations Report

Date and Working Program Title	Speaker Name, e-mail address	Credit Hrs	Total # of Registrants		# of Pharmacist s Receiving CE	Objectives were met	Activity met educational needs	Quality of faculty was satisfactory	Educational materials were useful	Teaching methods were effective	Learning assessment activities were appropriate	Activity did not promote particular product or company	Overall Activity Rating	Specialty Areas	Focus Areas (Outcomes, Safety, Best Practices)
Session CCO3: Data-Driven Formulary Management: Applying Analytic Tools to Drive Efficient Medication Use	Mark J. Sinnett, PharmD, FASHP Pavel Goriacko, PharmD, MPH, BCPS	1.0	3	1	1	4	4	4	4	4	4	4	4.00	IT, Pharmacy Administration	Best Practices
Session FHM6: Evaluating Risk Factors for MRSA and Pseudomonas in Community-acquired Pneumonia	Cameron Lanier, PharmD, MS, BCPS	1.0	3	1	1	5	5	5	5	5	5	5		Antimicrobial Stewardship	Outcomes
Session PSL1: A New Model for Pharmacy Surveillance in Long-Term Care	Colleen Culley, PharmD, BCPS	0.75	6	5	5	4.8	4.8	4.8	4.8	4.8	4.8	4.4	4.74	Long-term care	Best Practices
Session PSL2: Antimicrobial Stewardship: Implementing A Dalbavancin Program	Alison Ivey, PharmD, BCPS	1.0	5	4	4	4.75	4.75	4.75	4.75	4.75	4.75	4.75	475	Antimicrobial Stewardship	Outcomes, Best Practices
Session PSL3: Biosimilar Decision Making: Choose Wisely	Donald Herko, BS, CRCR Tim Speerhas, RPh	0.75	4	3	3	4.67	4.67	4.67 4.67	4.67	4.67	4.67	4.67	4.67	Biosimilars	Best Practices
Session PSL4: Biosimilars: Strategies for Successful Implementation at Moffitt Cancer Center: A Comprehensive Cancer Center	Kenneth Komorny, PharmD, BCPS	0.75	5	4	4	5	5	5	5	5	5	5	5.00	Biosimilars	Best Practices
Session PSL5: Developing a System-wide Compounding Quality Program	Amanda Wollitz, PharmD, BCPS, FISMP Christine Hong Phuah, BS	1.0	8	7	7	5	5	5 5	5	5	5	5	500 1	Pharmacy Administration	Best Practices
Session PSL6: Implementing a Clinical Pharmacy Dashboard	Marcia Hunt-Curran, PharmD, BCPS	1.0	10	9	9	4.56	4.56	4.56	4.67	4.67	4.67	4.67		Pharmacy Administration	Best Practices
Session PSL7: Improving Insulin Distribution in the Hospital Setting	Andrew Grimone, PharmD, BCPS, DPLA	0.5	5	4	4	5	5	5	5	5	5	5		Pharmacy Administration	Best Practices
Session PSL9: Precision Dosing Technology: Managing the New Vancomycin Guidelines	Jena Foreman, PharmD, BCPS, BCIDP Natalie Tucker, PharmD, BCPS, BCIDP	1.0	5	4	4	5	5	5 5	5	5	5	5	500	Antimicrobial Stewardship	Best Practices
Session PSL10: Tools to Transform Pharmacy: Today and Tomorrow	Karen McConnell, PharmD, MBS, FCCP, FASHP, BCPS	1.0	6	5	5	4.8	4.8	4.8	4.8	4.8	4.8	4.8		Pharmacy Administration	Best Practices
Session PSL12: Implementation of a Hybrid Admission Medication Reconciliation Program for Enhanced Transition of Care	Alison Walker, BS, CPhT Gene Merritt, PharmD	1.0	4	4	4	4.75	4.75	4.75 4.75	4.75	4.75	4.75	4.75	4.75	Transitions of Care	Best Practices

10.75 Please note: Session PSL8 was cancelled, and registrants for Session PSL11 did not complete the requirements to receive CE credit.

Totals

64 51

### Premier/Acurity, Inc. Homestudy CE Evaluations Report 2021 - Pharmacists

One of being first in the being requires and solutions basis in the being first in the beind first in the being first in the being first in the bei			Credit	Total # of	Total # of CE	# of Pharmacists	Objectives	Activity met educational	Quality of faculty was	Educational materials	Teaching methods were	Learning assessment activities were	Actively participated	Activity did not promote particular oroduct or	Overall		Focus Areas (Outcomes, Safety,
or Conversa         Subsitiants Partial         Subsite         Subsitiants Partia         Subsitian	Date and Working Program Title	Speaker Name, e-mail address		Registrants	Recipients	Receiving CE	were met	needs	satisfactory	were useful	effective	appropriate	in activity	company	Activity Rating	Specialty Areas	Best Practices)
Disk Skinger         Sector         Column         C	2018 Home Study CE: A Review of Opioid Pharmacotherapy for Acute	Maabo Kludze, PharmD, MBA, BCPS, CDE;	2.0	10	40	5	16	4.6	4.4	4	4.2	4.2	26	4.0	4 20	Dain Managamant	Optimizing Patient
370 A 400       500 bit standing constraints one intermaling constraints on intermaling constraints on intermaling constraints on intermaling constraints on intermaling constraints one intermaling constraints on intermaling cone intermaling constraint constraints on in	and Chronic Pain		2.0	13	12	5	4.0	4.0	4.4	4	4.2	4.2	3.0	4.0	4.30	· · · · · · · · · · · ·	Outcomes
CPU A 4020       Call B 4000 degree 3400 degree 34			10	91	57	41	4 64	4.61	46	4 58	4 51	4 54	4 26	4 55	4 54		Best Practices
Diame       Diame <thdiame< th=""> <thdiame< th=""> <thdi< td=""><td>&lt;797&gt; &amp; &lt;800&gt;</td><td></td><td>1.0</td><td></td><td>3/</td><td></td><td>+.04</td><td>4.01</td><td>4.0</td><td>4.00</td><td>4.01</td><td>-1.04</td><td>4.20</td><td>4.00</td><td>4.04</td><td></td><td></td></thdi<></thdiame<></thdiame<>	<797> & <800>		1.0		3/		+.04	4.01	4.0	4.00	4.01	-1.04	4.20	4.00	4.04		
2019         Descriptions         2019	2019 Home Study CE: Navigating the Beyond-Use Dating Landscape		1.0	45	34	23	4.51	4.43	4.37	4.41	4.34	4.34	4,19	4.33	4.37		Best Practices
Promote Delawers (Non-springer Al-Spring Markel)       Promote Markel (Markel)       P		joshua.soliman@nyumc.org	-	-	-											Regulations	
Agained and particips. Avaine     State States     Control     Contro     Control		Maabo Kludze, PharmD, MBA, BCPS, CDE;				-		4.55	4.50	4.50		4.50		4.50	4.50	<b>D</b> . 1 <i>1</i>	Optimizing Patient
Constraint         Control of the served part of the serv		Rachel Sussman, PharmD, BCPS	1.5	14	6	5	4.54	4.55	4.56	4.59	4.54	4.56	4.34	4.53	4.53	Diabetes	Outcomes
2012 Descension         Converges         10         42         39         20         4.6         4.20         4.60         4.80		Coitlun Cummingo, DharmD, BCDS;															
Care Family Registering         Draw Registering         Regis	2010 Home Study CE: Dearmonists Filling the Case in Transitions of																Ontimizing Patient
Image: contract in the problem of the prob	° 1		1.0	42	30	20	4.6	4.52	4.57	4.48	4.48	4.52	4.13	4.47	4.50	Transitions of Care	
2019 Horne Study CE       Los of the Play he Bills Bing wight og in Ambaland Carper Norman       10       89       62       44       4.53       4.46       4.49       4.45       4.45       4.47       4.24       4.53       4.46       Margement       Ben Prantage         2019 Mone Study CE       Moder Online Play he Bills Bing wight og       Prantage       10       48       15       4.57       4.67       4.63       4.46       4.41       4.53       4.44       4.55       4.66       4.11       4.54       4.54       6.45       6.45       4.51       4.55 <td></td> <td><b>o</b></td> <td></td> <td>Outcomes</td>		<b>o</b>															Outcomes
2019 Hand State/ 2: Looking Fee Hard berg the birg for get Hard Borg, ensingent Har		, , , , , , , , , , , , , , , , , , ,															
an. Modulary Care Selling     constance Parameter     constance	2019 Home Study CE: Looking Past the Pills to Pay the Bills: Billing in		10		62		4.52	4.40	4.40	4.54	4.45	4 47	4.04	4.54	4.46	Pharmacy	Deat Dreations
219 Home Study CE: Moder Challenges with the the of Vaccements       Low Matheling Repairs (Particle Particle Partecharter Particle Partecharter Partin Particle Partin Particle Pa	an Ambulatory Care Setting	0 0,	1.0	69	02	44	4.53	4.46	4.49	4.51	4.45	4.47	4.24	4.54	4.40	Management	Best Practices
Alty Data Study CE 1         Associating period         Assoc																-	0 F 11 D F 1
Keisey Keeing, Pranch, Jaskey Keeing, Pranch, Johan Jamma, Pranch, Johan Jamma, Pranch, Dankaus, Rightwa Garj Reinz Absham, Pranch, Jenesbarg, Briend, Darkaus, Rightwa Garj Reinz Absham, Pranch, Jenesbarg, Briend, Neuss, Rightwa Garj Reinz Absham, Pranch, Jenesbarg, Briend,	2019 Home Study CE: Modern Challenges with the Use of Vasopressin		1.0	48	18	15	4.67	4.67	4.63	4.56	4.56	4.6	4.1	4.54	4.54	Cardiovascular	
Application Safety Parts Home Study CPE 100 in plance 100 in pl																	Outcomes
2019 Medication Safety Pearls Home Study CE1       Solution Symmetry in Russes, RPN, WPA Paranol, Masses of Marka San, RPN, WPA Paranol, Reshub Rayan, Reaming, Reshub Rayan, Reshub Rayan, Reshub Rayan, Reaming, Reshub Rayan, Reshub Rashub Rayan, Reshub Rayan, Reshub Rayan,																	
2019 Medication Safety Pearls Home Study CE 1 Mark Rescale Drive Soft Medication Soft M																	
$\frac{1}{10000000000000000000000000000000000$	2010 Medication Safety Pearls Home Study CE 1		10	114	58	46	1 51	15	1.51	1.45	1.46	1 15	1 11	1.13	1 13	Medication Safety	Safety
$\frac{\text{Muscodighniston}}{\text{Muscodighniston}} \\ \frac{\text{Muscodighniston}}{\text{Muscodighniston}}{\text{Muscodighniston}} \\ \frac{\text{Muscodighniston}}{\text{Muscodighniston}} \\ $	Zers medication salety reans nome study of T		1.0			40	4.54	4.5	4.51	4.45	4.40	4.45	4.11	4.45	4.45	Medication Salety	Salety
Image: condition of the parameter of the p																	
Badika Pisagai. PhamD; pisagitabilities or Steven Nerebes(), PhamD, BCPS; murrang@uhg.org (hristine Kopec, RPh; dopec@uyhospital.org)         10         118         68         52         4.55         4.17         3.94         4.38         8         56         4.55         4.55         4.65         4.61         4.63         4.61         4.61         4.65         4.61         4.65         4.61         4.63         4.61         4.63         4.61         4.63         4.61         4.63																	
2019 Medication Safety Pearls Home Study CE 2       Steven Netroberg, PharmD, RCPS; nourang/durls org Divisition Kopec, RPH: dope copulsopsition       10       118       68       52       4.55      4.55      4.55       4.55																	
2019 Medication Safety Pearls Home Study CE 2       Marcia Curran, Pharm(b, CPS; mourand)gubg org       1.0       118       68       52       4.55 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>																	
$ \frac{Marca Curan, Pharmb, BCP; mourne@uhng.org}{Christine Kopee, RPh; ckopee, Quphospital.org}{Christine Kopee, RPh; ckopee, Quphospital.org}  $ $ \frac{Marca Curan, Pharmb, BCP; mourne@uhng.org}{Christine Kopee, RPh; ckopee, Quphospital.org}  $ $ 2020 Homestudy CE; EPA's New Hazardous Waste Pharmaceuticals  Charlote A. Smith, RPh, MS; centih32@wm.com 1.0 91 70 43 4.52 4.49 4.54 4.48 4.44 4.45 4.417 3.94 4.48 Pharmacy Laws and Regulations  Regulations  $ $ \frac{2020 Homestudy CE; Pharma Selfing and Productivity: ShoupAgounteent from the March Pharmb, BCPP; march Ph$	2019 Medication Safety Pearls Home Study CE 2		1.0	118	68	52	4.55	4.55	4.52	4.55	4.52	4.5	4.24	4,49	4,49	Medication Safety	Safety
2020 Homestudy CE:       EPA New Hazardous Waste Pharmaceuticals       Charlote A. Smith, RPh, MS; comitals 20m, com       1.0       91       70       43       4.52       4.49       4.46       4.46       4.17       3.94       4.38       Pharmacy Laws and Regulations       Regulations       Sate Value       Regulations       Sate Value       Regulations       Sate Value       Regulations		Marcia Curran, PharmD, BCPS; mcurran@uhhg.org		-													
Rule: log fair lakeawaysCount <td></td> <td>Christine Kopec, RPh; ckopec@wphospital.org</td> <td></td>		Christine Kopec, RPh; ckopec@wphospital.org															
Rule: log fair lakeawaysCount <td>2020 Homestudy CE: EPA's New Hazardous Waste Pharmaceuticals</td> <td>Charlette A. Creith, DDb, MC, comith 22@urp com</td> <td>4.0</td> <td>04</td> <td>70</td> <td>42</td> <td>4.50</td> <td>4.40</td> <td>4.54</td> <td>4.40</td> <td></td> <td>4.45</td> <td>4 47</td> <td>2.04</td> <td>4.20</td> <td>Pharmacy Laws and</td> <td>Cafabi</td>	2020 Homestudy CE: EPA's New Hazardous Waste Pharmaceuticals	Charlette A. Creith, DDb, MC, comith 22@urp com	4.0	04	70	42	4.50	4.40	4.54	4.40		4.45	4 47	2.04	4.20	Pharmacy Laws and	Cafabi
Leveraging Data to Demonstrate ValueSRouph@uwhealth.org2.04.32.4184.644.54.624.554.484.554.174.174.46ManagementBest Practices2020 Homestudy CE: Namestugy Namestage Namestugy CE: Namestugy Namestugy Namestage Namestugy Namestage Namestugy Namestage Namestugy Namestage Names	Rule: Top Ten Takeaways	Chanotte A. Smith, RPh, MS; csmith32@wm.com	1.0	91	70	43	4.52	4.49	4.04	4.40	4.44	4.40	4.17	3.94	4.38	Regulations	Salety
Leveraging Data to Demonstrate Value         SRough@unhealth.org         Chr.         No.         No. <th< td=""><td>2020 Homestudy CE: Pharmacy Benchmarking and Productivity:</td><td>Steve Rough, MS, RPh, FASHP;</td><td>2.0</td><td>43</td><td>24</td><td>10</td><td>1.61</td><td>15</td><td>4.62</td><td>1 55</td><td>1 18</td><td>4 55</td><td>4 17</td><td>4 17</td><td>4.46</td><td>Pharmacy</td><td>Post Prostings</td></th<>	2020 Homestudy CE: Pharmacy Benchmarking and Productivity:	Steve Rough, MS, RPh, FASHP;	2.0	43	24	10	1.61	15	4.62	1 55	1 18	4 55	4 17	4 17	4.46	Pharmacy	Post Prostings
Organizing Your Approach to Hazardous Drug Handling       CRoussel@dh.org       1.0       37       30       21       4.04       4.05       4.01			2.0	40	24	10	4.04	4.5	4.02	4.55	4.40	4.55	4.17	4.17	4.40	Management	Dest Flacilies
Organizing Your Approach to Hazardous Drug Handling         CROUSSE@dh.org         Image: CROU			10	37	30	21	4 64	4 66	4 65	4.61	4.63	4 61	4 36	4.6	4 60	Hazardous drugs	Safety
2020 Homestudy CE: Building and Optimizing Your Speciality       Aexander.Phan@bmc.org       1.0       23       10       7       4.57       4.57       4.64       4.39       4.46       4.57       4.64       4.64       4.67       4.64       4.67       4.64       4.67       4.64       4.67       4.64       4.67       4.67       4.66       4.67       4.66       4.67       4.66       4.67       4.66       4.67       4.66       4.67       4.66       4.67       4.66       4.67       4.66       4.67       4.66       4.67       4.66       4.67       4.66	Organizing Your Approach to Hazardous Drug Handling		1.0		30	21	+.04	4.00	4.00	4.01	4.00	4.01	4.00	4.0	4.00		ouloty
$\frac{2020 \text{ Homestudy CE: Building and Optimizing Your Speciality}}{Bhavesh Shah, RPh, BCOP; Bhavesh Shah, Qbmc.org}$ $\frac{1.0}{2020 \text{ Homestudy CE: Caution Ahead: Preventing Medication Errors in the Health-System Setting}}$ $2020 \text{ Homestudy CE: Caution Ahead: Preventing Medication of Every Residency Program and Student Curriculum – Preceptors MINNET Qmentefrine.org Mark J. Sinnett, PharmaCy, FASHP; ASHP; ASHP; ASHP; Curricultarie Pharmacy Team; pharm; pharmacy Team; pharmacy Team; pharmacy Te$									4 64								
Pharmacy       Bhavesh Shah, RPh, BCOP; Bhavesh Shah, Qbm.corg       Constant Management		0	1.0	23	10	7	4.57	4.5		4.39	4.46	4.5	4.32	4.34	4.46		Best Practices
2020 Homestudy CE:       Calculation Ahead: Preventing Medication Errors in the Health-System Setting       Christina Michalek, BS, RPh, FASHP; cmichalek@ismp.org       1.0       84       39       31       4.57       4.53       4.6       4.51       4.54       4.2       3.99       4.43       Medication Safety       Safety         2020 Homestudy CE:       The Foundation of Every Residency Program and Student Curriculum – Preceptors       Mark J. Sinnett, PharmD, FASHP; MSINNET Gomentefine corg       1.0       27       19       14       4.6       4.59       4.62       4.57       4.53       4.6       4.5       4.6       4.50       4.6       4.51       4.6       4.50       4.6       4.51       4.6       4.50       4.6       4.51       4.51       4.52       4.62       4.58       Medication Safety       Safety         2020 Homestudy CE:       Not Site Michalek, BS, RPh, FASHP; MSINP; MSIN	Pharmacy			-					4.46							Management	
the Health-System Setting       cmichalek@ismp.org       1.0       84       39       31       4.57       4.53       4.6       4.51       4.54       4.2       3.99       4.43       Medication Safety       Safety         2020 Homestudy CE:       The Foundation of Every Residency Program and Student Curriculum – Preceptors       Mark J. Sinnett, PharmD, FASHP; MSINNET@montefiore.org       1.0       27       19       14       4.6       4.59       4.62       4.57       4.53       4.6       4.55       4.64       4.2       3.99       4.43       Medication Safety       Safety         2020 Homestudy CE:       The Foundation of Every Residency Program and Student Curriculum – Preceptors       Mark J. Sinnett, PharmD, FASHP; MSINNET@montefiore.org       1.0       27       19       14       4.6       4.59       4.62       4.57       4.53       4.6       4.																	
International control legistry control legi	v		1.0	84	39	31	4.57	4.53	4.6	4.51	4.5	4.54	4.2	3.99	4.43	Medication Safetv	Safety
and Student Curriculum – Preceptors       MSINNET@montefiore.org       1.0       27       19       14       4.0       4.99       4.02       4.57       4.03       4.03       4.02       4.03       Development       Development         2020 Homestudy CE:																Drecenter	,
2020 Homestudy CE:         2020-Domestudy CE:         2020-Domestudy CE:         Converting of the convert			1.0	27	19	14	4.6	4.59	4.62	4.57	4.53	4.6	4.5	4.62	4.58		Best Practices
2020 Homestudy CE:         2020-2021 Influenza Virus and Vaccine Update         http://pharmacyteam@premierinc.com         1.0         28         19         10         4.66         4.67         4.66         -         4.69         4.67         Immunizations         Best Practices           2020 Homestudy CE:         2020-2021 Influenza Virus and Vaccine Update         pharmacyteam@premierinc.com         1.0         28         19         10         4.66         4.67         4.68         -         4.69         4.67         Immunizations         Best Practices           2020 Homestudy CE:         Consideration for Coagulation-Related Therapies         William Dager, Pharmb, BCPS, MCCM, FACCP, 10         91         14         10         4.59         4.56         4.58         4.56         4.58 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> </td><td></td><td></td><td></td><td></td><td></td><td>Development</td><td></td></td<>																Development	
	2020 Homestudy CE: 2020-2021 Influenza Virus and Vaccine Update		1.0	28	19	10	4.66	4.67	4.64	4.71	4.63	4.68	-	4.69	4.67	Immunizations	Best Practices
	2020 Homestudy CE: Consideration for Coagulation-Related Therapies																Ontimizing Patient
	In COVID-19	FCSHP. FASHP: wedager@ucdavis.edu	1.0	91	14	10	4.59	4.54	4.58	4.56	4.58	4.56	-	4.63	4.58	COVID-19	Outcomes

### Premier/Acurity, Inc. Homestudy CE Evaluations Report 2021 - Pharmacists

		Credit	Total # of		# of Pharmacists	Objectives	Activity met educational	Quality of faculty was	Educational materials	Teaching methods were		Actively participated	Activity did not promote particular product or	Overall		Focus Areas (Outcomes, Safety,
Date and Working Program Title	Speaker Name, e-mail address	Hrs	Registrants	Recipients	Receiving CE	were met	needs	satisfactory	were useful	effective	appropriate	in activity	company	Activity Rating	Specialty Areas	Best Practices)
2021 Homestudy CE: COVID-19 Vaccine: Science and Health-System	Karen McConnell, PharmD, FCCP, FASHP, BCPS; mailto:karenmcconnell@catholichealth.net Eric Yager, PhD; Eric.Yager@acphs.edu	1.0	77	56	45	4.58	4.6	4.64	4.58	4.56	4.56	-	4.64	4.59	COVID-19, Immunizations	Best Practices
Practice	Patricia C. Kienle, RPh, MPA, FASHP; Patricia.Kienle@cardinalhealth.com	1.0	220	129	101	4.55	4.57	4.6	4.55	4.54	4.52	-	4.59	4.56	Sterile Compounding	Best Practices
Present and Future	Regina McClinton, PhD; reginamcclinton@icloud.com	1.0	42	20	13	4.41	4.47	4.47	4.41	4.41	4.41	-	4.59	4.45	Diversity, Administrat	Best Practices
2021 Homestudy CE: Achieving and Sustaining USP <800> Compliance	Lilit Smith, PharmD, MBS, BCSCP; lilits@baptisthealth.net	1.0	60	29	23	4.5	4.58	4.58	4.54	4.54	4.54	-	4.54	4.55	Pharmacy Regulation	Best Practices
2021 Homestudy CE: COVID-19 Management and Therapeutics – What Lessons Did We Learn?	Debra Goff, PharmD, FIDSA, FCCP; debbie.goff@osumc.edu	1.0	39	3	2	4.79	4.79	4.79	4.79	4.79	4.79	-	4.79	4.79	COVID-19	Best Practices
Emergency Department	Nicole Acquisto, PharmD, FCCP, BCCCP; Nicole_Acquisto@URMC.Rochester.edu	1.0	129	96	75	4.64	4.61	4.62	4.61	4.61	4.62	-	4.64	4.62		Best Practices, Safety
2021 Homestudy CE: Integrating Biosimilars into Health Systems	Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA; Soefje.Scott@mayo.edu	1.0	70	35	28	4.55	4.52	4.55	4.52	4.48	4.48	-	4.55	4.52	Biosimilars, Cost- savings	Best Practices
2021 Homestudy CE: Laboratory Implementation of CLSI Updates: Recipe for Success	Wendy Szymczak, PhD, D(ABMM), MT(ASCP); wszymcza@montefiore.org	1.0	36	15	12	4.6	4.58	4.58	4.58	4.58	4.58	-	4.58	4.58	Antimicrobial Stewardship	Best Practices, Outcomes
2021 Homestudy CE: Opioid Stewardship	Jennifer Halsey, MS, PharmD, MHA, BCPS; jhalsey@peacehealth.org Nicholas Quinn, PharmD, BCCCP; nguinn@montefiore.org	1.0	82	40	30	4.54	4.56	4.56 4.54	4.54	4.54	4.56	-	4.59	4.55	Onioide	Safety, Best Practices, Outcomes
2021 Homestudy CE: Pharmacy Residency Preceptor Training:	Ashley Woodruff, PharmD, BCPS; aew7@buffalo.edu	1.0	125	65	57	4 54	4.47	4.54	4.51	4.46	4.46		4.56	4.51	Pharmacy Preceptor	Rest Practices
Teaching and Research Skills	Erin Slazak, PharmD, BCPS, BCACP; emsabia@buffalo.edu	1.0	120		51	4.54	4.47	4.56	4.01	4.40	4.40		4.50	4.01	Development	Dest i lactices
	Emily L. Heil, PharmD, MS, BCIDP, BCPS, AAHIVP; eheil@rx.umaryland.edu							4.53								
2021 Homestudy CE: Vancomycin AUC Implementation and Outcomes	Erin K. McCreary, PharmD, BCPS, BCIDP; mccrearye3@upmc.edu	1.0	62	16	15	4.53	4.47	4.53	4.53	4.59	4.53	-	4.53	4.53	Antimicrobial Stewardship	Best Practices, Outcomes
	Victor Chen, PharmD, BCPS, BCIDP; vic002@health.ucsd.edu							4.53								
2021 Homestudy CE: Vancomycin AUC/MIC Dosing: Improving the Target	Michael J. Rybak, PharmD, MPH, PhD; m.rybak@wayne.edu	1.0	216	108	98	4.5	4.49	4.5	4.49	4.42	4.44	-	4.5	4.48	Antimicrobial Stewardship	Best Practices, Outcomes
2021 Homestudy CE: Influenza Virus and Vaccine Update 2021-22	Elizabeth A. Shlom, PharmD, MBA, BCPS; eshlom@acurity.com	1.0	156	88	69	4.72	4.72	4.66	4.71	4.59	4.68	-	4.7	4.68	Immunizations	Best Practices
Totals		32.5	2318	1270	]											

## Premier/Acurity, Inc. Homestudy CE Evaluations Report 2021 - Pharmacy Technicians

		Credit	Total # of	Total # of CE	# of Pharmacy Technicians	Objectives	Activity met educational	Quality of faculty was	Educational materials	Teaching methods were	Learning assessment activities were	Actively participated	Activity did not promote particular product or	Overall		Focus Areas (Outcomes, Safety,
Date and Working Program Title	Speaker Name, e-mail address	Hrs	Registrants	Recipients	Receiving CE	were met	needs	satisfactory	were useful	effective	appropriate	in activity	company	Activity Rating	Specialty Areas	Best Practices)
2018 Home Study CE: A Review of Opioid Pharmacotherapy for Acute and Chronic Pain	Maabo Kludze, PharmD, MBA, BCPS, CDE; Rachel Sussman, PharmD, BCPS	2.0	19	12	7	4.33	4.00	4.00	4.50	4.50	4.50	3.67	4.17	4.21	Pain Management	Optimizing Patient Outcomes
2018 Home Study CE: Real-World Experience with USP Chapters <797> & <800>	Kevin Hansen, PharmD, MS, BCPS; 'Kevin.Hansen@conehealth.com'	1.0	91	57	16	4.53	4.57	4.47	4.57	4.51	4.47	4.06	4.25	4.43	Pharmacy Laws and Regulations	Best Practices
2019 Home Study CE: Navigating the Beyond-Use Dating Landscape	Joshua Soliman, PharmD; joshua.soliman@nyumc.org	1.0	45	34	11	4.37	4.28	4.24	4.33	4.24	4.13	3.96	4.22	4.22	Pharmacy Laws and Regulations	Best Practices
2019 Home Study CE: Efficacy and Safety of Non-Insulin Injectable Therapies for Diabetes Management: A Focus on GLP1Receptor Agonists and Pramlintide Acetate	Maabo Kludze, PharmD, MBA, BCPS, CDE; Rachel Sussman, PharmD, BCPS	1.5	14	6	1	4.38	4.38	4.38	4.38	4.38	4.38	4.38	4.38	4.38	Diabetes	Optimizing Patient Outcomes
2019 Home Study CE: Pharmacists Filling the Gaps in Transitions of Care: Panel Discussion	Caitlyn Cummings, PharmD, BCPS; ccummings5@northwell.edu; Emmanuel Knight, PharmD, BCPS, BCGP; knighte@montefiorenyack.org	1.0	42	30	10	4.30	4.27	4.23	4.27	4.23	4.20	3.90	4.18	4.20	Transitions of Care	Optimizing Patient Outcomes
2019 Home Study CE: Looking Past the Pills to Pay the Bills: Billing in an Ambulatory Care Setting	Elise M. Kim, PharmD, BCACP, BC-ADM; ekim@tbh.org;	1.0	89	62	18	4.18	4.18	4.23	4.20	4.09	4.09	3.91	4.18	4.13	Pharmacy Management	Best Practices
2019 Home Study CE: Modern Challenges with the Use of Vasopressin	Jerry Altshuler, PharmD, BCPS, BCCCP; Jerry.Altshuler@mountsinai.org	1.0	48	18	3	3.63	3.63	3.88	3.75	3.75	3.75	3.38	3.68	3.68	Cardiovascular	Optimizing Patient Outcomes
2019 Medication Safety Pearls Home Study CE 1	Kelsey Keeley, PharmD; kelsey.keeley@nyulangone.org Joshua Soliman, PharmD; joshua.soliman@nyumc.org Maria Russo, RPh, MPA, PharmD; MRusso@ghvhs.org Renu Abraham, PharmD: renabrah@montefiore.org	1.0	114	58	12	4.00	4.04	4.00	3.96	3.96	3.96	3.88	4.04	3.98	Medication Safety	Safety
	Radhika Pisupati, PharmD; pisupatr@sihmc.org Steven Nerenberg, PharmD; nerenbes@sihmc.org Marcia Curran, PharmD, BCPS; mcurran@uhhg.org Christine Kopec. RPh; ckopec@wohospital.org	1.0	118	68	16	4.25	4.29	4.36	4.39	4.32	4.39	4.00	4.29	4.29	Medication Safety	Safety
2020 Homestudy CE: EPA's New Hazardous Waste Pharmaceuticals Rule: Top Ten Takeaways	Charlotte A. Smith, RPh, MS; csmith32@wm.com	1.0	91	70	27	4.48	4.48	4.40	4.44	4.44	4.46	4.17	3.96	4.35	Pharmacy Laws and Regulations	Safety
	Steve Rough, MS, RPh, FASHP; SRough@uwhealth.org	2.0	43	24	6	3.94	4.11	4.00	4.00	4.00	4.00	4.00	3.89	3.99	Pharmacy Management	Best Practices
2020 Homestudy CE: Assessing the Risk: Understanding and Organizing Your Approach to Hazardous Drug Handling	Christine Roussel, PharmD, BCOP; CRoussel@dh.org	1.0	37	30	9	4.35	4.41	4.44	4.34	4.34	4.41	4.19	4.35	4.35	Hazardous drugs	Safety
	Alexander Pham, PharmD, MBA; Alexander.Pham@bmc.org Bhavesh Shah, RPh, BCOP; Bhavesh.Shah@bmc.org	1.0	23	10	3	3.67	3.67	3.83 3.83	3.83	4.17	3.83	3.83	3.83	3.83	Pharmacy Management	Best Practices
2020 Homestudy CE: Caution Ahead: Preventing Medication Errors in the Health-System Setting	Christina Michalek, BS, RPh, FASHP; cmichalek@ismp.org	1.0	84	39	8	4.47	4.32	4.21	4.21	4.26	4.26	3.74	3.89	4.17	Medication Safety	Safety
2020 Homestudy CE: The Foundation of Every Residency Program and Student Curriculum – Preceptors	Mark J. Sinnett, PharmD, FASHP; MSINNET@montefiore.org	1.0	27	19	5	4.20	4.30	4.30	4.30	4.30	4.30	4.30	4.30	4.29	Preceptor Development	Best Practices
2020 Homestudy CE: 2020-2021 Influenza Virus and Vaccine Update	Acurity & Premier Pharmacy Team; pharmacyteam@premierinc.com	1.0	38	19	9	4.50	4.43	4.43	4.46	4.36	4.36	-	4.46	4.43	Immunizations	Best Practices
2020 Homestudy CE: Consideration for Coagulation-Related Therapies in COVID-19	William Dager, PharmD, BCPS, MCCM, FACCP, FCSHP, FASHP; wedager@ucdavis.edu	1.0	91	14	4	4.38	4.25	4.38	4.38	4.38	4.38	-	4.38	4.36	COVID-19	Optimizing Patient Outcomes

## Premier/Acurity, Inc. Homestudy CE Evaluations Report 2021 - Pharmacy Technicians

		Credit		Total # of CE	# of Pharmacy Technicians	Objectives	Activity met educational	Quality of faculty was	Educational materials	Teaching methods were	Learning assessment activities were	Actively participated	Activity did not promote particular product or	Overall		Focus Areas (Outcomes, Safety,
Date and Working Program Title	Speaker Name, e-mail address	Hrs	Registrants	Recipients	Receiving CE	were met	needs	satisfactory	were useful	effective	appropriate	in activity	company	Activity Rating	Specialty Areas	Best Practices)
2021 Homestudy CE: COVID-19 Vaccine: Science and Health-System Logistics	Karen McConnell, PharmD, FCCP, FASHP, BCPS; mailto:karenmcconnell@catholichealth.net Eric Yager, PhD; Eric.Yager@acphs.edu	1.0	77	56	11	4.5	4.5	4.5	4.5	4.5	4.5	-	4.5	4.50	COVID-19, Immunizations	Best Practices
2021 Homestudy CE: Sterile Compounding: Planning for 2021 Best Practice	Patricia C. Kienle, RPh, MPA, FASHP; Patricia.Kienle@cardinalhealth.com	1.0	220	129	28	4.45	4.48	4.45	4.38	4.38	4.38	-	4.45	4.42	Sterile Compounding	Best Practices
2021 Homestudy CE: A Diverse Healthcare Workforce for America's Present and Future	Regina McClinton, PhD, reginamcclinton@icloud.com	1.0	42	20	7	4.3	4.2	4	4.1	4.2	4.2	-	4	4.14	Diversity, Administra	Best Practices
2021 Homestudy CE: Achieving and Sustaining USP <800> Compliance	Lilit Smith, PharmD, MBS, BCSCP; lilits@baptisthealth.net	1.0	60	29	6	4.5	4.5	4.5	4.38	4.38	4.38	-	4.5	4.45	Pharmacy Regulatio	r Best Practices
2021 Homestudy CE: COVID-19 Management and Therapeutics – What Lessons Did We Learn?	Debra Goff, PharmD, FIDSA, FCCP; debbie.goff@osumc.edu	1.0	39	3	1	4	4	4	4	4	4	-	4	4.00	COVID-19	Best Practices
2021 Homestudy CE: Creating a Safe Medication Environment in the Emergency Department	Nicole Acquisto, PharmD, FCCP, BCCCP; Nicole_Acquisto@URMC.Rochester.edu	1.0	129	96	21	4.27	4.27	4.27	4.27	4.23	4.27	-	4.27	4.26	Med Safety	Best Practices, Safet
2021 Homestudy CE: Integrating Biosimilars into Health Systems	Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA; Soefje.Scott@mayo.edu	1.0	70	35	7	4.5	4.38	4.38	4.38	4.38	4.38	-	4.38	4.40	Biosimilars, Cost- savings	Best Practices
2021 Homestudy CE: Laboratory Implementation of CLSI Updates: Recipe for Success	Wendy Szymczak, PhD, D(ABMM), MT(ASCP); wszymcza@montefiore.org	1.0	36	15	3	4.25	4.25	4.5	4.5	4.5	4.5	-	4.5	4.43	Antimicrobial Stewardship	Best Practices, Outcomes
2021 Homestudy CE: Opioid Stewardship	Jennifer Halsey, MS, PharmD, MHA, BCPS; jhalsey@peacehealth.org Nicholas Quinn, PharmD, BCCCP; nguinn@montefiore.org Asilley Woodorul, Finamuo, BCFS,	1.0	82	40	10	4.38	4.23	4.15 4.15	4.23	4.23	4.15	-	4.23	4.22	Opioids	Safety, Best Practices, Outcomes
2021 Homestudy CE: Pharmacy Residency Preceptor Training: Teaching and Research Skills	Erin Slazak, PharmD, BCPS, BCACP; emsabia@buffalo.edu	1.0	125	65	8	4.56	4.67	4.67 4.67	4.67	4.67	4.67	-	4.67	4.66	Pharmacy Preceptor Development	Best Practices
	Emily L. Heil, PharmD, MS, BCIDP, BCPS, AAHIVP; eheil@rx.umaryland.edu Erin K. McCreary, PharmD, BCPS, BCIDP;			10		15		4.5		15					Antimicrobial	Best Practices,
2021 Homestudy CE: Vancomycin AUC Implementation and Outcomes	mccrearye3@upmc.edu Victor Chen, PharmD, BCPS, BCIDP; vic002@health.ucsd.edu	1.0	62	16	1	4.5	3	4.5	4.5	4.5	3	-	4.5	4.17	Stewardship	Outcomes
2021 Homestudy CE: Vancomycin AUC/MIC Dosing: Improving the Target	Michael J. Rybak, PharmD, MPH, PhD; m.rybak@wayne.edu	1.0	216	108	10	4.18	4.18	4.18	4.27	4.18	4.27	-	4.18	4.21	Antimicrobial Stewardship	Best Practices, Outcomes
2021 Homestudy CE: Influenza Virus and Vaccine Update 2021-22	Elizabeth A. Shlom, PharmD, MBA, BCPS; eshlom@acurity.com	1.0	156	88	19	4.32	4.32	4.32	4.32	4.26	4.26	-	4.32	4.30	Immunizations	Best Practices
Totals		32.5	2328	1270												

# Premier/Acurity, Inc. CE Teleconference Comments Report 2021

Date and Activity Topic	Speaker(s)	Total # of Registrants	# of Participants receiving CE credit	# of Pharmacy Technicians receiving CE credit	Bias, promotion or commercial advertisement?	Comments (number of members with same response in parentheses)
January 27, 2021: COVID-19 Vaccine: Science and Health-system Logistics	Karen McConnell, PharmD, FCCP, FASHP, BCPS; mailto.karenmcconnell@catholichealth.net Eric Yager, PhD; Eric.Yager@acphs.edu	587	426	46	N/A/None (106)	1. Informative (23); 2. Knowledgeable (19); 3. Well prepared; clear presentation; 4. Good job; 5. Interesting (2); 6. Good/Very good/Great/Excellent speaker (10); 8. Good presenter; 9. Good/Very good/Great/Excellent clear ad concise (5); 11. Well spoken; easy to follow; 12. Covered the material well; 13. Nice job; 14. Excellent program; 15. Good/Very good/Great/Excellent presentation (4); 16. Very timely (2); 17. Well presented; 18. Great job; 19. Thorough; 20. Engaging; 21. Very comprehensive slides; 22. Excellent program; 32. Easy to understand; 24. Interesting
February 25, 2021: Integrating Biosimilars Into Health Systems	Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA; Soefje.Scott@mayo.edu	527	387	30	N/A/None (82)	<ol> <li>Very knowledgeable (18); 2. Good/Very good/Great/Excellent speaker (17); 3. Effective speaker; 4. Informative (21); 5. Good/Very good/Great/Excellent (11); 6.</li> <li>Clear/Concise (5); 7. Good/Very good/Great/Excellent presentation (8); 8. Engaging (2); 9. Well done (2); 10. Organized (2); 11. Able to provide a unique perspective; 12. Interesting (2); 13. Very thorough; 14. Great overview (2); 15. Easy to understand/follow (2); 16. Good evaluation; 17. Thoughtful and insightful questions; 18. Good lecture</li> </ol>
March 23, 2021: Strategic Planning for Health-System Pharmacy in Turbulent Times	John A. Armitstead, MS, RPh, FASHP; john.armitstead@leehealth.org	493	390	42	N/A/None (90)	<ol> <li>Clear/Concise (3); 2. Good/Very good/Great/Excellent (14); 3. Well done (3); 4. Very informative (14); 5. Engaging (3); 6. Good/Very good/Great/Excellent speaker (15); 7. Good/Very good/Great/Excellent presentation (11); 8. Smooth and down to earth; 9. Knowledgeable (8); 10. Nicely done; 11. Very enlightening; 12. Well versed on the subject; 13. [Speaker] leads by example; 14. Exceptional; 15. Wonderful speaker; 16. Thank you (3); 17. Interesting (2); 18. Helpful; 19. Very organized</li> </ol>
April 21, 2021: Pediatric Medication Error Prevention: Standardizing for a Non-Standard Patient	Bryan Blackwelder, PharmD; Bryan.Blackwelder@bmcjax.com	571	454	51		1. Very nice; 2. Good/Very good/Great/Excellent presentation/speaker (15); 3. Clear/Concise (3); 4. Easy to listen to; 5. Very knowledgeable (12); 6. Good safety review; 7. Good/Very good/Great/Excellent (15); 8. Well versed in subject matter; 9. Informative (15); 10. Thank you; 11. Detailed; 12. Great delivery; 13. Good/Very good/Great/Excellent job (3); 14. Well done (3); 15. Good references (2); 16. Very professional and thorough; 17. Very helpful; 18. Interesting; 19. Thorough
May 18, 2021: Managing the ICU Patient with Obesity	Brian Erstad, PharmD; erstad@pharmacy.arizona.edu	537	417	48	N/A/None (90)	<ol> <li>Very knowledgeable (17); 2. Informative (13); 3. Organized; 4. Good/Very good/Great/Excellent talk (2); 5. Good/Very good/Great/Excellent (8); 6. Good teaching skills; 7. A lot of data in a short period of time; 8. Well done (3); 9. Good/Very good/Great/Excellent (17); 10. Good/Very good/Great/Excellent speaker; 11. Very thorough and honest about the subject mattler; 12. Clear and concise (2); 13. Engaging speaker; 14. Great topic; 15. Very detailed; 16. Interesting (2); 17. Good job</li> </ol>
June 22, 2021: A Daily Infusion of Outpatient Parenteral Antibiotic Therapy (OPAT) Education	Monica V. Mahoney, PharmD, BCPS AQ-ID, BCIDP; mmahoney@bidmc.harvard.edu	514	392	45	N/A/None (76)	<ol> <li>Good/Very good/Great/Excellent presentation (11); 2. Good flow/pace (2); 3. Solid; 4. Very knowledgeable (11); 5. Very intelligent, enthusiastic and engaging; 6. Easy to understand; 7. Good/Very good/Great/Excellent job (5); 8. Good/Very good/Great/Excellent speaker (13); 9. Amazing speaker; 10. Clear/Concise (4); 11. Very informative (18); 12. Very engaging; 13. Very organized; 14. Easy to follow; 15. Good/Very good/Great/Excellent (6); 16. Very elaborate and didactic; 17. Interesting; 18. Well done (4); 19. Awesome presentation; 20. Very detailed; 21. Educational</li> </ol>
	Nicholas Quinn, PharmD, BCCCP; nquinn@montefiore.org	500	422	45		1. Good/Very good/Great/Excellent presentation (9); 2. Good/Very good/Great/Excellent job (2); 3. Loved [Dr. Quinn's] speaking style; 4. Constructive; 5. Good/Very good/Great/Excellent (7); 6. Clear/Concise (4); 7. Succinct (2); 8. Excellent delivery; 9. Good/Very good/Great/Excellent speaker (6); 10. Knowledgeable (9); 11. Engaging (3); 12. Well done (2); 13. Interesting (2); 14. Thankful for the information; 15. Good job; 16. Good cadence
July 28, 2021: Pain Management in the ICU (Working Title)	Jennifer Halsey, MS, PharmD, BCPS; jhalsey@peacehealth.org	562	422	45		1. Good/Very good/Great/Excellent presentation (8); 2. Succinct (2); 3. Informative (12); 4. Good/Very good/Great/Excellent job (3); 5. Interesting (3); 6. Knowledgeable (8); 7. Good/Very good/Great/Excellent speaker (7); 8. Good/Very good/Great/Excellent (7); 9. Great talk and clinical pearls; 10. Engaging (3); 11. Good detail; needed more time; 12. Clear/Concise; 13. Thank you (2); 14. Well done (2); 15. Slides needed more detail; 16. Effective speaker
August 19, 2021: Pharmacotherapy Management of Patients with Pulmonary Arterial Hypertension	Heather Torbic, PharmD, BCCCP, BCPS; torbich@ccf.org	515	346	41	N/A/None (59)	1. Clear/Concise (2); 2. Good/Very good/Great/Excellent presentation (10); 3. Very organized (3); 4. Knowledgeable (6); 5. Well done (3); 6. Good/Very good/Great/Excellent speaker (7); 7. Good/Very good/Great/Excellent (14); 8. Good overview of a challenging topic; 9. Very thorough; 10. Good analysis; 11. Informative (6); 12. Interesting
September 23, 2021: Update on COVID-19 Therapeutics: What Have We Learned So Far? (Working Title)	Debra Goff, PharmD, FIDSA, FCCP; debbie.goff@osumc.edu	565	428	54	N/A/None (79)	<ol> <li>Knowledgeable (14): 2. Good/Very good/Great/Excellent speaker (15); 3. Great pacing; 4. Good/Very good/Great/Excellent presentation (8); 5. Good/Very good/Great/Excellent (12); 6. Clear/Concise (4); 7. Phenomenal presentation; 8. I enjoyed the presentation (6); 9. Brilliant presenter; 10. Great discussion; very insightfuit; 11. Thank you; 12. Wonderful job; 13. Informative (14); 14. Interesting (13); 15. Awesome presentation; 16. Easy to understand; 17. Well done (2); 18. Engaging (2); 19. Very timely topic; 20. Easy to understand; 21. Gave a better description of the latest COVID-19 treatment for patients; 22. Effective</li> </ol>
October 19. 2021: Update on Federal Pharmacy Laws (Working Title)	Soumi Saha, PharmD, JD; soumi_saha@premierinc.com	524	415	56	N/A/None (96)	<ol> <li>Clear/Concise (9); 2. Easy to follow; 3. Nice job; 4. Wonderful; 5. Informative (21); 6. Nice presentation; 7. Thank you; 8. Relevant (2); 9. Amazing presenter; 10.</li> <li>Very comprehensive presentation; 11. Very knowledgeable (14); 12. Engaging (3); 13. Good/Very good/Great/Excellent (7); 14. Good/Very good/Great/Excellent (7); 15. Good/Very dod/Great/Excellent (7); 15. Great/gob; 20. Dynamic speaker; 21. Good overview; 22. Entertaining</li> </ol>
November 17, 2021: Sickle Cell: The Past, the Present, and the Future	Ashley Siryk, PharmD; asiryk@mhs.net	546	388	49		<ol> <li>Clear/Concise (7); 2. Good pace (2); 3. Very informative (15); 4. Good/Very good/Great/Excellent (12); 5. Good/Very good/Great/Excellent speaker (16); 6. Very thorough (2); 7. Knowledgeable (9); 8. Good talk (2); 9. Fantastic speaker and teacher; 10. Very good overview; 11. Interesting (2); 12. Could have emphasized the toll sickle cell anemia takes on the African-American community; 13. Awesome speaker; 14. Engaging (3); 15. Good job (2); 16. Good/Very good/Great/Excellent presentation (4); 17. Well done (2)</li> </ol>
<u>December 16, 2021</u> : The Use of SGLT2 Inhibitors for Heart Failure Management	Judy Cheng, PharmD, MPH, FCCP, BCPS, RPh; judy.cheng@mcphs.edu	606	439	49	N/A/None (77)	<ol> <li>Knowledgeable (15); 2. Good/Very good/Great/Excellent presentation (11); 3. Clear/Concise (11); 4. The best speaker I've heard in years; 5. Interesting (3); 6. Good/Very good/Great/Excellent job (7); 7. Good/Very good/Great/Excellent speaker (16); 8. I enjoyed the presentation (3); 9. Easy to understand (2); 10. Very informative (22); 11. Hard to distinguish between HFpEF and HFrEF; 12. Good/Very good/Great/Excellent (8); 13. Very nice presentation; 14. Well presented; 15. Very good reinforcement of concepts; 16. Very easy to follow; 17. Provided very good practical approach to offer this treatment option (2); 18. Very well done; 19. Detailed (2); 20. Effective speaker (2); 21. Thank you (2)</li> </ol>

### Premier/Acurity, Inc. Pharmacy Practice Forum Comments Report 2021

Date and Activity Topic	Speaker(s)	Total # of Registrants	# of Participants receiving CE credit	# of Pharmacy Technicians receiving CE credit	Bias, promotion or commercial advertisement?	Comments (number of members with same response in parentheses)
	Lauren Ribaudo, PharmD, BCPS, BCCCP; Lribaudo@garnethealth.org					<ol> <li>Good/Very Good/Great/Excellent speaker (5); 2. Good/Very good/Great/Excellent (9); 3. Knowledgeable (4); 4. Good/Very good/Great/Excellent (2); 5. Interesting (3); 6. Well organized (2); 7. Very timely information; 8. Nice job; 9. Good/Very good/Great/Excellent presentation; 10. Wonderful job; 11. Very well presented; 12. Very informative (7); 13. Thank you; 14. Helpful information; 15. Appreciated new information; 16. [Dr. Ribaudo] was phenomenal</li> </ol>
	Corey Frederick, PharmD, BCPS, BCIDP; cfrederick@mhs.net	516	375	35		<ol> <li>Good/Very Good/Great/Excellent (14); 2. Excellent topic; 3. Very informative (20); 4. Strong work; 5. Good/Very good/Great/Excellent pace (3); 6. Engaging (2); 7. Succinct; 8. Good/Very good/Great/Excellent presentation (10); 9. Well presented; 10. Very effective speaker and presenter; 11. Knowledgeable (13); 12. Organized (3); 13. Spoke fast (4); 14. [Speaker] did good; 15. Good/Very good/Great/Excellent speaker (7); 16. Clear/Concise (3); 17. Great job (2); 18. Well done; 19. Thorough; 20. Interesting; 21. Amazing comprehensive review</li> </ol>
	Dianeysis H. Avendano PharmD, CPh, BCPS; davendano@mhs.net	469	343	42		Knowledgeable; 2. Good/Very good/Great/Excellent (9); 3. Good/Very good/Great/Excellent speaker (7); 4. Informative (19); 5. Very detailed; 6.Good/Very good/Great/Excellent job (2); 7. Clear/Concise (10); 8. Good reinforcement of current hospital pharmacy practices (2); 9. Easy to understand (2); 10. Thank you; 11. Good/Very good/Great/Excellent presentation (3); 12. Thorough (3); 13. Interesting (3)
May 5, 2021: Medication Safety: Handling Hazardous Medication (Interim Title)	Lilit Smith, PharmD, MBA, BCSCP; LilitS@baptisthealth.net	519	383	49		<ol> <li>Thank you (2); 2. Good/Very good/Great/Excellent presentation (10); 3. Informative (10); 4. Easy to listen to; 5. Clear and concise (3); 6. Good/Very good/Great/Excellent (9); 7. Good/Very good/Great/Excellent (9); 7. Good/Very good/Great/Excellent job (4); 8. Good/Very good/Great/Excellent speaker (8); 9. Very thorough; 10. Knowledgeable (6); 11. Nice (2); 12. Well presented; 13. Interesting; 14. Well done; 15. Nicely done; 16. Clear recommendations</li> </ol>
July 14, 2021: A Diverse Healthcare Workforce for America's Present and Future	Regina McClinton, PhD, CDP; reginamc@med.umich.edu	463	348	42		<ol> <li>Good/Very good/Great/Excellent (10); 2. Good/Very good/Great/Excellent speaker (14); 3. Energetic (3); 4. Passionate about topic (2); 5. Enthusiastic (3);</li> <li>Well planned; 7. Informative (16); 8. Motivated (2); 9. Engaging (5); 10. Great job; 11. Clear and concise (2); 12. Interesting (2); 13. Excellent talk; 14. Good presentation; 15. Knowledgeable; 16. Excellent use of imagery and examples</li> </ol>
	Suzanne Turner, PharmD, FASHP; suzanne.turner@leehealth.org	566	405	60		1. Good/Very good/Great/Excellent (19); 2. Informative (15); 3. Good pace; 4. Organized (3); 5. Knowledgeable (3); 6. Well prepared; 7. Good/Very good/Great/Excellent speaker (12); 8. Very engaging (2); 9. Relevant (2); 10. Nice presentation; 11. Good/Very good/Great/Excellent presentation (11); 12. Gave great ideas (2); 13. Clear/Concise (2); 14. Helpful presentation (2); 15. Great job; 16. Easy to follow; 17. Very passionate about the topic; 18. Interesting (2); 19. Enlightening; 20. Insightful
	Carolyn J. Oxencis, PharmD, BCOP; carolyn.oxencis@froedtert.com	500	400	00		<ol> <li>Clear/Concise; 2. Informative (17); 3. Organized (2); 4. Knowledgeable (5); 5. Good/Very good/Great/Excellent speaker (9); 6. Nice presentation; 7.</li> <li>Good/Very good/Great/Excellent (9); 8. Gave great ideas (2); 9. Good experience examples; 10. Good/Very good/Great/Excellent (13); 11. Great job (3); 12.</li> <li>Relevant; 13. Terrific speaker; 14. Easy to follow along; 15. Very passionate about the topic; 16. Engaging; 17. Provided good examples (2); 18. Very helpful; 19. Interesting; 20. Enlightening; 21. Awesome</li> </ol>
November 4, 2021: Insulin: Pharmacy Advancements in Inpatient	Andy Grimone, PharmD, BCPS; andrew.grimone@vidanthealth.com	497	323	41	N/A/None (59)	1. Novel idea for insulin distribution; greatly appreciated; 2. Good/Very good/Great/Excellent presentation (6); 2. Knowledgeable (3); 3. Clear/Concise (3); 4. Good/Very good/Great/Excellent job (3); 5. Informative (13); 6. Dr. Grimone presented very well; 7. Good topic; 8. Great insight; 9. Good/Very good/Great/Excellent (8); 10. Good/Very good/Great/Excellent speaker (10); 11. Provided exciting prospects; 12. Provided a thorough overview; 13. Innovative approach; 14. Brief and sweet; 15. Interesting (3); 16. Very important topic; 17. Very timely; 18. Activities were very productive
Distribution and Patient Management	Jubie Joseph, PharmD; jubie.joseph@snch.org		323			<ol> <li>Thank you for sharing. 2. Good/Very good/Great/Excellent presentation (7): 3. Good/Very good/Great/Excellent job (4): 4. Very good material; 5. Good/Very good/Great/Excellent speaker (7): 6. Informative (9); 7. Very detailed; 8. Interesting (4): 9. Good review of her facility's program; 10. Good/Very good/Great/Excellent (7): 11. Test questions were based on Dr. Joseph's facility protocol; no best practice was discussed; 12. Knowledgeable (4); 13. Very well done; 14. Clear/Concise (2); 15. Reinforced what we practice currently</li> </ol>

#### Premier/Acurity, Inc. Antimicrobial Stewardship Forum Comments Report 2021

Date and Activity Topic	Speaker(s) Yi Guo, PharmD, BCIPD; yiguo@montefiore.org	Total # of Registrants	s receiving	receiving	Bias, promotion or commercial advertisement?	Comments (number of members with same response in parentheses) 1. Very informative (16); 2. Very knowledgeable (9); 3. Very effective; 4. Good/Very good/Great/Excellent speaker (10); 5. Clear/Concise (7); 6. Good/Very good/Great/Excellent presentation (10); 7. Good/Very good/Great/Excellent (10); 8. Interesting (2); 9. Excellent job; 10. Weil researched and thorough
February 10, 2021: What's HOT in Antimicrobial Stewardship: Updates from ID Week 2020	Nita Roy, PharmD; RoyN@southcoast.org	502	340	29	N/A/None (73)	1. Very informative (16); 2. Clear/Concise (6); 3. Very effective; 4. Good/Very good/Great/Excellent speaker (7); 5. Explained information well; 6. Good/Very good/Great/Excellent presentation (6); 7. Good/Very good/Great/Excellent (9); 8. Well spoken; 9. Knowledgeable (5); 10. Very relevant topic; 11. Spoke a little too fast; 12. Timely topic (2); 13. Slides could be more condensed; 14. Constructive and educational; 15. Interesting; 16. Effective communicator; 17. Excellent job; 18. Well done; 19. A terrific presentation
	Wendy Szymczak, PhD, D(ABMM), MT(ASCP); wszymcza@montefiore.org	444	309	43	N/A/None (57)	1. Very effective; 2. Excellent presentation (11); 3. Clear/Concise (6); 4. Good/Very good/Great/Excellent (8); 5. Organized (3); 6. Informative (13); 7. Good pace; 8. Knowledgeable (6); 8. Enjoyed her presentation; 9. Good/Very good/Great/Excellent speaker (6); 10. Fantastic presentation; 11. Well done; 12. Not appropriate for pharmacy technicians; 13. Interesting; 14. Wonderful
	Julie E. Williamson, PharmD, BCPS; Julie.Williamson@atriumhealth.org	476	355	39	N/A/None (75)	1. Very thorough; 2. Informative (15); 3. Good/Very good/Great/Excellent (8); 4. Extremely effective presentation; 5. Good flow; 6. Good/Very good/Great/Excellent speaker (15); 7. Knowledgeable (10); 8. Wonderfui; 9. Great topic; 10. Tour de force presentation; 11. Good/Very good/Great/Excellent presentation (6); 12. Clear/Concise (6); 13. Well done; 14. Very competent; 15. Great use of best practices and literature; 16. Interesting (3); 17. Well organized; 18. Very elaborate; 19. Intelligent speaker; 20. Good job; 21. Great representation of statistical data
	Erin K. McCreary, PharmD, BCPS, BCIDP; mccrearye3@upmc.edu					<ol> <li>Good/Very good/Great/Excellent (10); 2. Knowledgeable (10); 3. Very informative (17); 4. Awesome presentation (2); 5. Thank you (4); 6. Very practical presentation; 7. Good/Very good/Great/Excellent speaker (15); 8. Engaging; 9. Excellent tips for a successful program; 10. Had difficulty answering some of the questions which referenced the 2020 vancomycin guidelines; 11. Clear/Concise (4); 12. Energetic; 13. Good/Very good/Great/Excellent presentation (8); 14. Excellent job; 15. Detail oriented (2); 16. Strong points made and clarifications provided; 17. Good content; 18. Very efficient; 19. Very good work; 20. Too much time spent on site implementation and not enough on doing sample calculations based on monitored data; 21. Interesting; 22. Positive; 23. Very cutting-edge delivery; 24. Precise</li> </ol>
(Working due)	Emily L. Heil, PharmD, MS, BCIDP, BCPS, AAVIHP; eheil@rx.umaryland.edu	757	483	37	N/A/None (95)	1. Knowledgeable (14); 2. Thank you (5); 3. Appreciated [speaker's] experience; 4. Very nice overview with useful tips; 5. Good/Very good/Great/Excellent (9); 6. Good/Very good/Great/Excellent (3); 7. Excellent job (2); 8. Had difficulty answering some of the questions which referenced the 2020 vancomycin guidelines; 9. Enthusiastic speaker (15); 7. Excellent job (2); 8. Had difficulty answering some of the questions which referenced the 2020 vancomycin guidelines; 9. Enthusiastic speaker (15); 7. Excellent job (2); 8. Had difficulty answering some of the questions which referenced the 2020 vancomycin guidelines; 9. Enthusiastic speaker (15); 7. I. Informative (15); 12. Clear/Concise (6); 13. Good ortent; 14. Very efficient; 15. Fantastic job; 16. Detailed explanation of protocol (2); 17. Too much time spent on site implementation and not enough on doing sample calculations based on monitored data; 18. Interesting; 19. Speaker was fine; 20. Positive; 21. Excellent program implementation; 22. Engaging; 23. Keep up the good work [1. Good/Very good/Great/Excellent (11); 2. Knowledgeable (11); 3. Good/Very good/Great/Excellent presentation; (6), 4. Thank you (5); 5. Good/Very
	Victor Chen, PharmD, BCPS, BCIDP; vic002@health.ucsd.edu					1. Good/Very
October 6, 2021: Antimicrobial Stewardship in the Emergency Department (Working title)	Cierra N. Treu, PharmD, BCCCP; cnt9004@nyp.org	565	417	44	N/A/None (101)	1. Good/Very good/Great/Excellent speaker (16); 2. Very knowledgeable (11); 3. Thank you (2); 4. Good/Very good/Great/Excellent presentation (15); 5. Excellent insight into ED-based pharmacy work; 6. Good/Very good/Great/Excellent job (3); 7. Confident speaker; 8. Good/Very good/Great/Excellent (16); 9. Great delivery; spoke clearly; 10. Clear/Concise (7); 11. Interesting (2); 12. Professional; 13. Visually pleasing slides; 14. Very nice presentation; 15. Very informative (15); 16. Efficient and to the point; 17. Engaging (2); 18. Very thorough (3); 19. She was awesome; 20. Well done; 21. Effective speaker; 22. Enthusiastic
December 1, 2021: Short-Course Antibiotic Treatment (Working title)	Yuman (Yumi) Lee, PharmD, BCIDP; leey2@stjohns.edu	524	390	48	NA/None (98)	<ol> <li>Good/Very good/Great/Excellent presentation (12); 2. Knowledgeable (10); 3. Good rate and diction; 4. Informative (21); 5. Clear/Concise (7); 6. Well done; 7. Good/Very good/Great/Excellent (9); 8. Actual cases could have been included to support the literature (2); 9. Good/Very good/Great/Excellent speaker (10); 10. Organized; 11. Good/Very good/Great/Excellent job (4); 12. Nice overview; 13. Interesting (3); 14. Dr. Lee presented very nicely; 15. Well versed and thorough; 16. Easy to follow (2); 17. Effective presentation; 18. Thank you; 19. Easy to understand; 20. Excellent command of the literature</li> </ol>

Date and Activity Topic	Speaker(s)	Total # of Registrant s	# of Participants receiving CE credit	# of Pharmacy Technicians receiving CE credit	Bias, promotion or commercial advertisement?		Comments (number of members with same response in parentheses)
2018 Home Study CE: A Review of Opioid Pharmacotherapy for Acute		19	12	7	N/A/None (1)	N/A/None (1)	None
and Chronic Pain 2018 Home Study CE: Real-World Experience with USP Chapters <797> & <800>	Sussman, PharmD, BCPS Kevin Hansen, PharmD, MS, BCPS; Kevin.Hansen@conehealth.com	91	57	16	N/A/None (31)	N/A/None (24)	None
2019 Home Study CE: Navigating the Beyond-Use Dating Landscape	Joshua Soliman, PharmD; joshua.soliman@nyumc.org	45	34	11	N/A/None (31)	N/A/None (45)	Presenter seemed to push for "taking a stand" against using package inserts
2019 Home Study CE: Efficacy and Safety of Non-Insulin Injectable Therapies for Diabetes Management: A Focus on GLP1Receptor Agonists and Pramlintide Acetate	Maabo Kludze, PharmD, MBA, BCPS, CDE; Rachel Sussman, PharmD, BCPS	14	6	1	N/A/None (6)	N/A/None (7)	None
2019 Home Study CE: Pharmacists Filling the Gaps in Transitions of Care: Panel Discussion	Caitlyn Cummings, PharmD, BCPS; ccummings5@northwell.edu; Emmanuel Knight, PharmD, BCPS, BCGP; knighte@montefiorenyack.org	42	30	10	N/A/None (14)	N/A/None (7); Objectives were met (4)	It was good
2019 Home Study CE: Looking Past the Pills to Pay the Bills: Billing in an Ambulatory Care Setting	Elise M. Kim, PharmD, BCACP, BC-ADM; ekim@tbh.org; Evan Sasson, PharmD, BCPS; esasson@tbh.org	89	62	18	N/A/None (17)	N/A/None (8); Objectives were met (4)	None
2019 Home Study CE: Modern Challenges with the Use of Vasopressin	Jerry Altshuler, PharmD, BCPS, BCCCP; Jerry.Altshuler@mountsinai.org	48	18	3	N/A/None (10)	N/A/None (5)	Effective and targeted information; easy to understand
2019 Medication Safety Pearls Home Study CE 1	Kelsey Keeley, PharmD; kelsey.keeley@nyulangone.org Joshua Soliman, PharmD; joshua.soliman@nyumc.org Maria Russo, RPh, MPA, PharmD; MRusso@ghvhs.org Renu Abraham, PharmD; renabrah@montefiore.org	114	58	12	N/A/None (9)	N/A/None (9); Objectives were met (2)	None
2019 Medication Safety Pearls Home Study CE 2	Radhika Pisupati, PharmD; pisupatr@sjhmc.org Steven Nerenberg, PharmD; nerenbes@sjhmc.org Marcia Curran, PharmD, BCPS; mcurran@uhhg.org Christine Kopec, RPh; ckopec@wphospital.org	118	68	16	N/A/None (17)	N/A/None (12); Objectives were met (1)	None
2020 Homestudy CE: EPA's New Hazardous Waste Pharmaceuticals Rule: Top Ten Takeaways	Charlotte A. Smith, RPh, MS; csmith32@wm.com	91	70	27	N/A/None (18)	Objectives were	<ol> <li>Good/Very good/Great/Excellent (2); 2. Presentation was well organized; 3. Nice job; 4. Great presentation;</li> <li>[Speaker] was wonderful; 6. Knowledgeable (2); 7. Informative; 8. Nice comparison of EPA vs. USP HDs; 9. Excellent speaker; 10 Great job</li> </ol>
2020 Homestudy CE: Pharmacy Benchmarking and Productivity: Leveraging Data to Demonstrate Value	Steve Rough, MS, RPh, FASHP; SRough@uwhealth.org	43	24	6	N/A/None (3)	N/A/None (5); Objectives were met (1)	1. Very informative; 2. Good presentation; 3. Unique and interesting; 4. Good
2020 Homestudy CE: Assessing the Risk: Understanding and Organizing Your Approach to Hazardous Drug Handling	Christine Roussel, PharmD, BCOP; CRoussel@dh.org	37	30	9	N/A/None (17)	N/A/None (15); Objective were met (1)	None
2020 Homestudy CE: Building and Optimizing Your Specialty Pharmacy	Alexander Pham, PharmD, MBA; Alexander.Pham@bmc.org Bhavesh Shah, RPh, BCOP; Bhavesh.Shah@bmc.org	23	10	3	N/A/None (2)	N/A/None (1)	None
2020 Homestudy CE: Caution Ahead: Preventing Medication Errors in the Health-System Setting	Christina Michalek, BS, RPh, FASHP; cmichalek@ismp.org	84	39	8	N/A/None (29)	N/A/None (55); Objectives were met (29)	<ol> <li>Good/Very good/Great/Excellent presentation (3); 2. Easy to listen to; 3. Well done; 4. Clear/Concise; 5.</li> <li>Great pace; 6. Thank you; 7. Good; 8. Knowledgeable; 9. Thorough; easy to understand; 10. Informative (2);</li> <li>11. Good/Very good/Great/Excellent job (2); 12. Well organized</li> </ol>
2020 Homestudy CE: The Foundation of Every Residency Program and Student Curriculum – Preceptors	Mark J. Sinnett, PharmD, FASHP; MSINNET@montefiore.org	27	19	5	N/A/None (5)	N/A/None (4); Objectives were met (1)	1. Valuable information; 2. Great slides; 3. Interesting; 4. Excellent CE presentation
2020 Homestudy CE: 2020-2021 Influenza Virus and Vaccine Update	Acurity & Premier Pharmacy Team; pharmacyteam@premierinc.com	38	19	9	N/A/None (15)	N/A/None (5)	None
2020 Homestudy CE: Consideration for Coagulation-Related Therapies in COVID-19	wedager@ucdavis.edu	91	14	4	N/A/None (9)	N/A/None (4)	1. Knowledgeable; 2. Thorough; 3. Concise; 4. Easy to understand; 5. Thank you
2021 Homestudy CE: COVID-19 Vaccine: Science and Health-System I poistics	Karen McConnell, PharmD, FCCP, FASHP, BCPS; mailto:karenmcconnell@catholichealth.net	77	56	11	N/A/None (8)	N/A/None (4)	1. Informative (2); 2. Well done; 3. Up-to-date and comprehensive material

### Premier/Acurity, Inc. Homestudy CE Comments Report 2021

Date and Activity Topic	Speaker(s)		# of Participants receiving CE credit		Bias, promotion or commercial advertisement?	Objectives that were <u>not</u> met	Comments (number of members with same response in parentheses)
	Eric Yager, PhD; Eric.Yager@acphs.edu						
2021 Homestudy CE: Sterile Compounding: Planning for 2021 Best Practice	Patricia C. Kienle, RPh, MPA, FASHP; Patricia Kienle@cardinalhealth.com	220	129	28	N/A/None (15)	N/A/None (9)	1. Very knowledgeable (2); 2. Nice talk; 3. Good job; 4. Informative (2); 5. Well done; 5. Good/Very good/Great/Excellent (2)
2021 Homestudy CE: A Diverse Healthcare Workforce for America's Present and Future	Regina McClinton, PhD; reginamcclinton@icloud.com	42	20	7	N/A/None (18); Logo was everywhere	N/A/None (21); Objectives were met (2)	1. Good job; 2. Good/Very good/Great/Excellent (3); 3. Well presented and paced; 4. Interesting (2)
2021 Homestudy CE: Achieving and Sustaining USP <800> Compliance	Lilit Smith, PharmD, MBS, BCSCP; lilits@baptisthealth.net	60	29	6	N/A/None (5)	N/A/None (4)	1. Wonderful examples; 2. Knowledgeable; 3. Nice job; detailed slides; 4. Thorough and well spoken
2021 Homestudy CE: COVID-19 Management and Therapeutics – What Lessons Did We Learn?	Debra Goff, PharmD, FIDSA, FCCP; debbie.goff@osumc.edu	39	3	1	N/A/None (2)	N/A/None (2)	Clear and concise
2021 Homestudy CE: Creating a Safe Medication Environment in the Emergency Department	Nicole Acquisto, PharmD, FCCP, BCCCP; Nicole_Acquisto@URMC.Rochester.edu	129	96	21		Objectives were met (5)	<ol> <li>Materials were helpful; 2. Could not hear the speaker; 3. Wonderful; 4. Excellent presentation (2); 5. Great talk; 6. Great examples throughout the presentation (2); 7. Well done; 8. Excellent; 9. Excellent job; 10. Knowledgeable</li> </ol>
2021 Homestudy CE: Integrating Biosimilars into Health Systems	Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA; Soefje.Scott@mayo.edu	70	35	7	N/A/None (4)	Objectives were met (2)	Excellent presentation
2021 Homestudy CE: Laboratory Implementation of CLSI Updates: Recipe for Success	Wendy Szymczak, PhD, D(ABMM), MT(ASCP); wszymcza@montefiore.org	36	15	3	N/A/None (1)	N/A/None (2)	None
	Jennifer Halsey, MS, PharmD, MHA, BCPS; jhalsey@peacehealth.org	- 82	40	10	N/A/None (5)		Great job
2021 Homestudy CE: Opioid Stewardship	Nicholas Quinn, PharmD, BCCCP; nquinn@montefiore.org	02	40	10	N/A/None (5)	Objectives were met	Knowledgeable
2021 Homestudy CE: Pharmacy Residency Preceptor Training:	Ashley Woodruff, PharmD, BCPS; aew7@buffalo.edu	125	65	8	N/A/None (5)	N/A/None (2)	1. wonderful; 2. Excellent; 3. Knowledgeable; 4. Well organized and presented effectively
Teaching and Research Skills	Erin Slazak, PharmD, BCPS, BCACP; emsabia@buffalo.edu	125	60	0	N/A/NOTe (5)	N/A/NORE (2)	1. Excellent (2); 2. Great presentation; 3. Easy to understand
	Emily L. Heil, PharmD, MS, BCIDP, BCPS, AAHIVP; eheil@rx.umaryland.edu						
2021 Homestudy CE: Vancomycin AUC Implementation and Outcomes	Erin K. McCreary, PharmD, BCPS, BCIDP; mccrearye3@upmc.edu	62	16	1	N/A/None (1)	N/A/None (1); Objectives were met (1)	None
	Victor Chen, PharmD, BCPS, BCIDP; vic002@health.ucsd.edu					met (1)	
2021 Homestudy CE: Vancomycin AUC/MIC Dosing: Improving the Target	Michael J. Rybak, PharmD, MPH, PhD; m.rybak@wayne.edu	216	108	10	N/A/None (7)	N/A/ None (1); Objectives were met (2)	1. Would have liked to see more "head-to-head" comparisons; 2. Knowledgeable (4); 3. Well organized & easy to follow; 4. Relevant information
2021 Homestudy CE: Influenza Virus and Vaccine Update 2021-22	Elizabeth A. Shlom, PharmD, MBA, BCPS; eshlom@acurity.com	156	88	19	N/A/None (39)	N/A/ None (29); Objectives were met (3)	None

#### Premier/Acurity, Inc. Premier Member Meeting, Capstone & Yankee Alliance CE Comments Report 2021

#### Premier Member Meeting

Date and Activity Topic	Speaker(s)		receiving CE		Bias, promotion or commercial advertisement?	
	Jeannell M. Mansur, RPh, PharmD, FASHP, FSMSO, CJCP; jmansur@jcrinc.com	1.0	499	38	N/A/None (57)	1. Good/Very good/Great/Excellent presentation (5); 2. Great job (2); 3. Very knowledgeable (4); 3. Very informative (12); 4. Thank you for the updates; 5. Provides practical experience/advice; 6. Good/Very good/Great/Excellent speaker (8); 7. Clear/Concise; 8. Very professional; 9. Good overview; Good/Very good/Great/Excellent (6); 10. Challenging learning assessment questions; 11. Very experienced surveyor; 12. Great topic; 13. Interesting (3); 14. Fantastic speaker; 15. Amazing job; 16. Very confusing topic; 17. Comprehensive and understandable

#### Capstone CEs

Date and Activity Topic	Speaker(s)				Bias, promotion or commercial advertisement?	
19: Focus on ICU and ID Patients with COVID-	Karen McConnell, PharmD, FCCP, FASHP, BCPS; mailto:karenmcconnell@catholichealth.net	19	9	0	N/A/None (1)	1. Very informative; 2. Thank you for a great program
April 29, 2021: Measuring the Immeasurable: Measuring Clinical Pharmacy Productivity	Eric Yager, PhD; Eric:Yager@acphs.edu Karen McConnell, PharmD, FCCP, FASHP, BCPS; mailto:karenmcconnell@catholichealth.net	15	7	1	N/A/None (5)	1. Well organized; 2. Good/Very good/Great/Excellent speaker (2); 3. Informative; 4. Good/Very good/Great/Excellent presentation (2); 5. Wonderful job; 6. Great overview
July 29, 2021: Using Clinical Surveillance to Improve Nephrotoxic Stewardship	Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP; kane-gill@pitt.edu	16	6	0	N/A/None (6)	1. Excellent presentation
October 28, 2021: Data-Driven Formulary	Pavel Goriacko, PharmD, MPH, BCPS; pgoriack@montefiore.org	18	14	14	N/A/None (6)	1. Good/Very good/Great/Excellent presentation (3); 2. Excellent speaker; 3. Excellent; 4. Easy to follow; 5. Great collaboration with Dr. Sinnett
THE REAL PROPERTY AND A DRIVE	Mark Sinnett, PharmD, FASHP; msinnet@montefiore.org					1.Good/Very good/Great/Excellent presentation (3); 2. Excellent speaker; 3. Excellent; 4. Easy to understand; 5. Great job

#### Yankee Alliance CEs

Date and Activity Topic	Speaker(s)	Total # of Registrants		Receiving CE	Bias, promotion or commercial advertisement?	
	Karen McConnell, PharmD, FCCP, FASHP, BCPS; mailto:karenmcconnell@catholichealth.net	12	10	0	N/A/None (3)	1. Very solid style, content and timeliness; 2. Engaging and enthusiastic; 3. Great presentation
	Soumi Saha, PharmD, JD; soumi_saha@premierinc.com	13	8	0	N/A/None (2)	1. Easy to understand; 2. Great speaker; engaging; 3. Great presentation

### Premier/Acurity Breakthroughs 2021 Comments Report

Date and Activity Topic	Speaker(s)	Total # of Registrants	Participants receiving CE credit	Pharmacists receiving CE credit	Bias, promotion or commercial advertisement?	Comments (number of members with same response in
Session CCO3: Data-Driven Formulary Management: Applying Analytic Tools to Drive Efficient Medication Use	Mark J. Sinnett, PharmD, FASHP Pavel Goriacko, PharmD, MPH, BCPS	3	1	1	N/A/None (1)	None
Session FHM6: Evaluating Risk Factors for MRSA and Pseudomonas in Community-acquired Pneumonia	Cameron Lanier, PharmD, MS, BCPS	3	1	1	N/A/None (1)	Excellent presentation
Session PSL1: A New Model for Pharmacy Surveillance in Long-Term Care	Colleen Culley, PharmD, BCPS	6	5	5	N/A/None (5)	None
Session PSL2: Antimicrobial Stewardship: Implementing A Dalbavancin Program	Alison Ivey, PharmD, BCPS	5	4	4	N/A/None (4)	None
Session PSL3: Biosimilar Decision Making: Choose Wisely	Donald Herko, BS, CRCR Tim Speerhas, RPh	4	3	3	N/A/None (3)	None
Session PSL4: Biosimilars: Strategies for Successful Implementation at Moffitt Cancer Center: A Comprehensive Cancer Center	Kenneth Komorny, PharmD, BCPS	5	4	4	N/A/None (4)	None
Session PSL5: Developing a System-wide Compounding Quality Program	Amanda Wollitz, PharmD, BCPS, FISMP Christine Hong Phuah, BS	8	7	7	N/A/None (7)	Great job
Session PSL6: Implementing a Clinical Pharmacy Dashboard	Marcia Hunt-Curran, PharmD, BCPS	10	9	9	N/A/None (9)	None
Session PSL7: Improving Insulin Distribution in the Hospital Setting	Andrew Grimone, PharmD, BCPS, DPLA	5	4	4	N/A/None (4)	None
Session PSL9: Precision Dosing Technology: Managing the New Vancomycin Guidelines	Jena Foreman, PharmD, BCPS, BCIDP Natalie Tucker, PharmD, BCPS, BCIDP	5	4	4	N/A/None (4)	Great presentation
Session PSL10: Tools to Transform Pharmacy: Today and Tomorrow	Karen McConnell, PharmD, MBS, FCCP, FASHP, BCPS	6	5	5	N/A/None 5)	None
Session PSL12: Implementation of a Hybrid Admission Medication Reconciliation Program for Enhanced Transition of Care	Alison Walker, BS, CPhT Gene Merritt, PharmD	4	4	4	N/A/None (4)	None

Please note: Session PSL8 was cancelled, and registrants for Session PSL11 did not complete the requirements to receive CE credit.

# Premier/Acurity, Inc. 2021 Overall CE Activity Ratings

			Total # of	
		Total # of		<b>Overall Activity</b>
Date and Activity Topic	Speaker(s)	Registrants		Rating
		Registratits	- Kecipiein	Nauny
	TeleCEs			
	Karen McConnell, PharmD, FCCP, FASHP, BCPS;			
January 27, 2021: COVID-19 Vaccine: Science and Health-system Logistics	mailto:karenmcconnell@catholichealth.net	587	426	4.47
	Eric Yager, PhD; Eric.Yager@acphs.edu			
February 25, 2021: Integrating Biosimilars Into Health Systems	Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA;	527	387	4.35
	Soefje.Scott@mayo.edu John A. Armitstead, MS, RPh, FASHP;	-		
March 23, 2021: Strategic Planning for Health-System Pharmacy in Turbulent Times	john.armitstead@leehealth.org	493	390	4.34
April 21, 2021: Pediatric Medication Error Prevention: Standardizing for a Non-Standard	Bryan Blackwelder, PharmD; Bryan.Blackwelder@bmcjax.com	571	454	4.37
Patient	, , , , , , , , , , , , , , , , , , , ,		-	
May 18, 2021: Managing the ICU Patient with Obesity	Brian Erstad, PharmD; erstad@pharmacy.arizona.edu	537	417	4.40
June 22, 2021: A Daily Infusion of Outpatient Parenteral Antibiotic Therapy (OPAT) Education	Monica V. Mahoney, PharmD, BCPS AQ-ID, BCIDP; mmahoney@bidmc.harvard.edu	514	392	4.40
	Nicholas Quinn, PharmD, BCCCP; nquinn@montefiore.org			
July 28, 2021: Opioid Stewardship	Jennifer Halsey, MS, PharmD, BCPS; jhalsey@peacehealth.org	562	422	4.38
August 19, 2021: Pharmacotherapy Management of Patients with Pulmonary Arterial	Heather Torbic, PharmD, BCCCP, BCPS; torbich@ccf.org	515	346	4,36
Hypertension	incarior robio, rinamio, booor, boro, tobioli@cci.org	515	040	4.50
September 23, 2021: COVID-19 Management and Therapeutics: What Lessons Did We Learn?	Debra Goff, PharmD, FIDSA, FCCP; debbie.goff@osumc.edu	565	428	4.45
October 19, 2021: An Inflection Point for Healthcare: Washington DC Advocacy Update	Soumi Saha, PharmD, JD; soumi saha@premierinc.com	524	415	4.42
<b>November 17, 2021</b> : Sickle Cell Disease Treatment: The Past, the Present, and the				
Future	Ashley Siryk, PharmD; asiryk@mhs.net	546	388	4.36
December 16, 2021: The Use of SGLT2 Inhibitors for Heart Failure Management	Judy Cheng, PharmD, MPH, FCCP, BCPS, RPh;	606	439	4.41
	judy.cheng@mcphs.edu			
	ASFs	1		1
February 10, 2021: What's HOT in Antimicrobial Stewardship: Updates from ID Week 2020	Yi Guo, PharmD, BCIPD; yiguo@montefiore.org Nita Roy, PharmD; RoyN@southcoast.org	502	340	4.29
	Wendy Szymczak, PhD, D(ABMM), MT(ASCP);			
April 7, 2021: Laboratory Implementation of CLSI Updates: Recipe for Success	wszymcza@montefiore.org	444	309	4.29
June 2, 2021: Expanding Antimicrobial Stewardship Efforts in the Outpatient Setting	Julie E. Williamson, PharmD, BCPS;	476	355	4.42
	Julie.Williamson@atriumhealth.org	470		-1.72
	Erin K. McCreary, PharmD, BCPS, BCIDP; mccrearye3@upmc.edu			
August 11, 2021: Vancomycin AUC Implementations and Outcomes (Working title)	Emily L. Heil, PharmD, MS, BCIDP, BCPS, AAVIHP;	757	483	4.30
<u></u>	eheil@rx.umaryland.edu			
	Victor Chen, PharmD, BCPS, BCIDP; vic002@health.ucsd.edu			
October 6, 2021: Antimicrobial Stewardship in the Emergency Department: Beyond the	Cierra N. Treu, PharmD, BCCCP; cnt9004@nyp.org	565	417	4.44
Bugs and Drugs December 1, 2021: Short and Sweet: Why is Shorter Duration of Antibiotic Therapy Better?		524		4.33
December 1, 2021: Short and Sweet. Why is Shorter Duration of Antibiotic Therapy Better?		524	390	4.33
	PPFs Lauren Ribaudo, PharmD, BCPS, BCCCP;			
January 14, 2021: Managing Patients with COVID-19: Focus on ICU and ID Patients	Lribaudo@garnethealth.org	516	375	4.39
<u></u>	Corey Frederick, PharmD, BCPS, BCIDP; cfrederick@mhs.net	1		
March 10, 2021: Utilizing Technology in Sterile Compounding Areas	Dianeysis H. Avendano PharmD, CPh, BCPS;	469	343	4.41
	davendano@mhs.net			
May 5, 2021: Medication Safety: Handling Hazardous Medication (Interim Title)	Lilit Smith, PharmD, MBA, BCSCP; LilitS@baptisthealth.net	519	383	4.40
July 14, 2021: A Diverse Healthcare Workforce for America's Present and Future	Regina McClinton, PhD, CDP; reginamc@med.umich.edu Suzanne Turner, PharmD, FASHP;	463	348	4.31
	suzanne turner, Pharmb, FASHP, suzanne.turner@leehealth.org			
September 9, 2021: New Approaches to Prevent Preceptor Burnout	Carolyn J. Oxencis, PharmD, BCOP;	506	363	4.41
	carolyn.oxencis@froedtert.com			
November 4, 2021: Insulin: Pharmacy Advancements in Inpatient Distribution and Patient	Andy Grimone, PharmD, BCPS;	407	200	4.00
Management	andrew.grimone@vidanthealth.com Jubie Joseph, PharmD; jubie.joseph@snch.org	497	323	4.38
	Capstone CEs	I	1	
	Lauren Ribaudo, PharmD, BCPS, BCCCP;			
January 28, 2021: Managing Patients with COVID-19: Focus on ICU and ID Patients	Lribaudo@garnethealth.org	19	9	4.67
	Corey Frederick, PharmD, BCPS, BCIDP; cfrederick@mhs.net			

# Premier/Acurity, Inc. 2021 Overall CE Activity Ratings

Date and Activity Topic	Speaker(s)			Overall Activity Rating
April 29, 2021: Measuring the Immeasurable: Measuring Clinical Pharmacy Productivity	Karen McConnell, PharmD, FCCP, FASHP, BCPS; mailto:karenmcconnell@catholichealth.net	15	7	4.68
July 29, 2021: Using Clinical Surveillance to Improve Nephrotoxic Stewardship	Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP; kane- gill@pitt.edu	16	6	4.77
October 28, 2021: Data-Driven Formulary Management: Applying Analytic Tools to Drive Efficient Medication Use	Pavel Goriacko, PharmD, MPH, BCPS; pgoriack@montefiore.org Mark Sinnett, PharmD, FASHP; msinnet@montefiore.org	18	14	4.85
	Yankee Alliance CEs			
October 20, 2021: An Inflection Point for Healthcare: Washington DC Advocacy Update	Soumi Saha, PharmD, JD; soumi_saha@premierinc.com	13	8	4.75
October 20, 2021: Tools to Transform Pharmacy: Today and Tomorrow	Karen McConnell, PharmD, FCCP, FASHP, BCPS; mailto:karenmcconnell@catholichealth.net	12	10	4.68
2021 P	remier Member Meeting CE			
December 2, 2021: Complex Orders: Compliance With Joint Commission Requirements	Jeannell Mansur, RPh, PharmD, FASHP, FSMSO; JMansur@jcrinc.com	499	265	4.33
	Home Study CEs			
2018 Home Study CE: A Review of Opioid Pharmacotherapy for Acute and Chronic Pain	Maabo Kludze, PharmD, MBA, BCPS, CDE; Rachel Sussman, PharmD, BCPS	19	12	4.25
2018 Home Study CE: Real-World Experience with USP Chapters <797> & <800>	Kevin Hansen, PharmD, MS, BCPS; 'Kevin.Hansen@conehealth.com'	91	57	4.56
2019 Home Study CE: Navigating the Beyond-Use Dating Landscape	Joshua Soliman, PharmD; joshua.soliman@nyumc.org	45	34	4.29
2019 Home Study CE: Efficacy and Safety of Non-Insulin Injectable Therapies for Diabetes Management: A Focus on GLP1Receptor Agonists and Pramlintide Acetate	Maabo Kludze, PharmD, MBA, BCPS, CDE; Rachel Sussman, PharmD, BCPS Cantyri Cummings, Finanne, BCFS,	14	6	4.45
2019 Home Study CE: Pharmacists Filling the Gaps in Transitions of Care: Panel Discussion	ccummings5@northwell.edu; Emmanuel Knight, PharmD, BCPS, BCGP;	42	30	4.34
2019 Home Study CE: Looking Past the Pills to Pay the Bills: Billing in an Ambulatory Care Setting	Elise M. Kim, PharmD, BCACP, BC-ADM; ekim@tbh.org; Evan Sasson, PharmD, BCPS; esasson@tbh.org	89	62	4.30
2019 Home Study CE: Modern Challenges with the Use of Vasopressin	Jerry Altshuler, PharmD, BCPS, BCCCP; Jerry.Altshuler@mountsinai.org	48	18	4.11
2019 Medication Safety Pearls Home Study CE 1	Kelsey Keeley, PharmD; kelsey keeley@nyulangone.org Joshua Soliman, PharmD; joshua.soliman@nyumc.org Maria Russo, RPh, MPA, PharmD; MRusso@ghvhs.org Renu Abraham, PharmD; renabrah@montefiore.org	114	58	4.21
2019 Medication Safety Pearls Home Study CE 2	Radhika Pisupati, PharmD; pisupatr@sjhmc.org Steven Nerenberg, PharmD; nerenbes@sjhmc.org Marcia Curran, PharmD, BCPS; mcurran@uhhg.org Christine Kopec, RPh; ckopec@wphospital.org	118	68	4.39
2020 Homestudy CE: EPA's New Hazardous Waste Pharmaceuticals Rule: Top Ten Takeaways	Charlotte A. Smith, RPh, MS; csmith32@wm.com	91	70	4.37
2020 Homestudy CE: Pharmacy Benchmarking and Productivity: Leveraging Data to Demonstrate Value	Steve Rough, MS, RPh, FASHP; SRough@uwhealth.org	43	24	4.23
2020 Homestudy CE: Assessing the Risk: Understanding and Organizing Your Approach to Hazardous Drug Handling	Christine Roussel, PharmD, BCOP; CRoussel@dh.org	37	30	4.47
2020 Homestudy CE: Building and Optimizing Your Specialty Pharmacy	Alexander Pham, PharmD, MBA; Alexander.Pham@bmc.org Bhavesh Shah, RPh, BCOP; Bhavesh.Shah@bmc.org	23	10	4.15
2020 Homestudy CE: Caution Ahead: Preventing Medication Errors in the Health-System Setting	Christina Michalek, BS, RPh, FASHP; cmichalek@ismp.org	84	39	4.30
2020 Homestudy CE: The Foundation of Every Residency Program and Student Curriculum – Preceptors	Mark J. Sinnett, PharmD, FASHP; MSINNET@montefiore.org	27	19	4.44
2020 Homestudy CE: 2020-2021 Influenza Virus and Vaccine Update	Acurity & Premier Pharmacy Team; pharmacyteam@premierinc.com	38	19	4.55
2020 Homestudy CE: Consideration for Coagulation-Related Therapies in COVID-19	William Dager, PharmD, BCPS, MCCM, FACCP, FCSHP, FASHP; wedager@ucdavis.edu	91	14	4.47

# Premier/Acurity, Inc. 2021 Overall CE Activity Ratings

	1	Total # of		
Date and Activity Topic	Speaker(s)	Total # of Registrants	CE Credit	Overall Activity Rating
2021 Homestudy CE: COVID-19 Vaccine: Science and Health-System Logistics	Karen McConnell, PharmD, FCCP, FASHP, BCPS; mailto:karenmcconnell@catholichealth.net Eric Yager, PhD; Eric.Yager@acphs.edu	77	56	4.55
2021 Homestudy CE: Sterile Compounding: Planning for 2021 Best Practice	Patricia C. Kienle, RPh, MPA, FASHP; Patricia.Kienle@cardinalhealth.com	220	129	4.49
2021 Homestudy CE: A Diverse Healthcare Workforce for America's Present and Future	Regina McClinton, PhD, reginamcclinton@icloud.com	42	20	4.30
2021 Homestudy CE: Achieving and Sustaining USP <800> Compliance	Lilit Smith, PharmD, MBS, BCSCP; lilits@baptisthealth.net	60	29	4.50
2021 Homestudy CE: COVID-19 Management and Therapeutics – What Lessons Did We Learn?	Debra Goff, PharmD, FIDSA, FCCP; debbie.goff@osumc.edu	39	3	4.40
2021 Homestudy CE: Creating a Safe Medication Environment in the Emergency Department	Nicole Acquisto, PharmD, FCCP, BCCCP; Nicole_Acquisto@URMC.Rochester.edu	129	96	4.44
2021 Homestudy CE: Integrating Biosimilars into Health Systems	Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA; Soefje.Scott@mayo.edu	70	35	4.46
2021 Homestudy CE: Laboratory Implementation of CLSI Updates: Recipe for Success	Wendy Szymczak, PhD, D(ABMM), MT(ASCP); wszymcza@montefiore.org	36	15	4.51
2021 Homestudy CE: Opioid Stewardship	Jennifer Halsey, MS, PharmD, MHA, BCPS; jhalsey@peacehealth.org Nicholas Quinn, PharmD, BCCCP; nquinn@montefiore.org	82	40	4.39
2021 Homestudy CE: Pharmacy Residency Preceptor Training: Teaching and Research Skills	Ashley Woodruff, PharmD, BCPS; aew7@buffalo.edu Erin Slazak, PharmD, BCPS, BCACP; emsabia@buffalo.edu	- 125	65	4.58
2021 Homestudy CE: Vancomycin AUC Implementation and Outcomes	Emily L. Heil, PharmD, MS, BCIDP, BCPS, AAHIVP; eheil@rx.umaryland.edu Erin K. McCreary, PharmD, BCPS, BCIDP; mccrearye3@upmc.edu Victor Chen, PharmD, BCPS, BCIDP; vic002@health.ucsd.edu	62	16	4.35
2021 Homestudy CE: Vancomycin AUC/MIC Dosing: Improving the Target	Michael J. Rybak, PharmD, MPH, PhD; m.rybak@wayne.edu	216	108	4.34
2021 Homestudy CE: Influenza Virus and Vaccine Update 2021-22	Elizabeth A. Shlom, PharmD, MBA, BCPS; eshlom@acurity.com		88	4.49
	reakthroughs 2021 CEs			
Session CCO3: Data-Driven Formulary Management: Applying Analytic Tools to Drive Efficient Medication Use	Mark J. Sinnett, PharmD, FASHP Pavel Goriacko, PharmD, MPH, BCPS	- 3	1	4.00
Session FHM6: Evaluating Risk Factors for MRSA and Pseudomonas in Community- acquired Pneumonia	Cameron Lanier, PharmD, MS, BCPS	3	1	5.00
Session PSL1: A New Model for Pharmacy Surveillance in Long-Term Care	Colleen Culley, PharmD, BCPS	6	5	4.74
Session PSL2: Antimicrobial Stewardship: Implementing A Dalbavancin Program	Alison Ivey, PharmD, BCPS	5	4	4.75
Session PSL3: Biosimilar Decision Making: Choose Wisely	Donald Herko, BS, CRCR	- 4	3	4.67
Session PSL4: Biosimilars: Strategies for Successful Implementation at Moffitt Cancer Center: A Comprehensive Cancer Center	Tim Speerhas, RPh Kenneth Komorny, PharmD, BCPS	5	4	5.00
Session PSL5: Developing a System-wide Compounding Quality Program	Amanda Wollitz, PharmD, BCPS, FISMP Christine Hong Phuah, BS	- 8	7	5.00
Session PSL6: Implementing a Clinical Pharmacy Dashboard	Marcia Hunt-Curran, PharmD, BCPS	10	9	4.62
Session PSL7: Improving Insulin Distribution in the Hospital Setting	Andrew Grimone, PharmD, BCPS, DPLA	5	4	5.00
Session PSL9: Precision Dosing Technology: Managing the New Vancomycin Guidelines	Jena Foreman, PharmD, BCPS, BCIDP	- 5	4	5.00
Section BSI 10: Tools to Transform Dearmon's Today and Tomarray	Natalie Tucker, PharmD, BCPS, BCIDP Karen McConnell, PharmD, MBS, FCCP, FASHP, BCPS	6	F	4.80
Session PSL10: Tools to Transform Pharmacy: Today and Tomorrow Session PSL12: Implementation of a Hybrid Admission Medication Reconciliation	Alison Walker, BS, CPhT	6 - 4	5	4.80
Program for Enhanced Transition of Care	Gene Merritt, PharmD			

Please note: For the Breakthroughs CEs, Session PSL8 was cancelled, and and registrants for Session PSL11 did not complete the requirements to receive CE credit.